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Zusammenfassung 
 
Das strikt human pathogene Varicella-Zoster Virus (VZV) gehört zur Familie der Herpesvi-
ren und ist weltweit verbreitet. Die Seroprävalenz beträgt über 95%. Die Primärinfektion 
von VZV verursacht Varicellen (Windpocken), eine typische Krankheit bei Kindern, welche 
durch Fieber und  einen disseminierten bläschenartigen Hautausschlag charakterisiert ist. 
Im Anschluss daran etabliert VZV eine lebenslange Latenz in sensorischen Ganglien und 
verursacht nach Reaktivierung Herpes Zoster (Gürtelrose). Dieser ist durch unilaterale, ve-
sikuläre Eruptionen, meistens innerhalb eines Dermatoms, gekennzeichnet. Häufig treten 
nach Herpes Zoster schmerzhafte Neuralgien auf. Seit 1995 wird ein Lebendimpfstoff aus 
attenuierten Virionen des VZV-Stammes V-Oka in den Vereinigten Staaten von Amerika 
erfolgreich eingesetzt, um Kinder gegen Varicellen zu immunisieren. Seit 2004 ist die Vari-
cellen-Schutzimpfung für alle Kinder und Jugendlichen in Deutschland empfohlen worden. 
Im Gegensatz zur Infektion mit zirkulierenden virulenten VZV Stämmen tritt nach Verimp-
fung des Vakzin-Stammes V-Oka kein Exanthem auf. Entscheidend für die Eliminierung der 
VZV Infektion ist die T-Zell-vermittelte Immunität. Zudem korreliert die altersbedingte Ab-
nahme der VZV-spezifischen T-Zell Immunität mit dem Anstieg der Inzidenz für Herpes Zos-
ter und schmerzhaften Neuralgien.  
Die Haut ist der Hauptreplikationsort von VZV. Immunologische Unterschiede zwi-
schen virulenten VZV Stämmen und dem Vakzin-Stamm treten hier am deutlichsten auf. 
Diese Unterschiede wurden bisher noch nicht näher untersucht. Kutane Immunzellen, wie 
zum Beispiel Langerhans Zellen (LC), dermale Dendritische Zellen (DDC), inflammatorische 
Dendritische Zellen und intraepitheliale γδ T-Zellen sind entscheidend am Aufbau antivira-
ler Immunantworten beteiligt. In dieser Studie lag daher ein Fokus auf dem Vergleich von 
kutanen Immunantworten zwischen virulenten VZV-Stämmen und dem Vakzin-Stamm. 
Daher wurden klinische Isolate von VZV Genotypen, die in Europa zirkulieren, in diese Stu-
die miteinbezogen. 
In der vorliegenden Arbeit wurde das Verschwinden von LC in Hautläsionen von Her-
pes Zoster Patienten beobachtet. Im Gegensatz dazu, wurde eine massive Infiltration von 
myeloiden inflammatorischen DC nachgewiesen. Ferner wurde hier zum ersten Mal ge-
zeigt, dass ex vivo isolierte LC und DDC permissiv für eine VZV Infektion sind. Von besonde-
rer Bedeutung war die Erkenntnis, dass keine Unterschiede zwischen dem Vakzin-Stamm V-
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Oka und virulentem VZV auftraten. In vitro Studien mit Monozyten abgeleiteten Dendriti-
schen Zellen (DC), welche inflammatorische DC repräsentieren, zeigten, dass diese sowohl 
vom Vakzin-, als auch von virulentem VZV-Stamm mit gleicher Effizienz infiziert wurden. 
Erstaunlicherweise konnte eine signifikant erhöhte Expression von CD1c Molekülen auf 
VZV infizierten DC nachgewiesen werden. Funktionelle Untersuchungen mit intraepithelia-
len CD1c-restringierten γδ T Zellen zeigten, dass DC nach Infektion mit dem Vakzin-Stamm 
V-Oka phänotypisch und funktionell reiften und somit die γδ T Zellen zur IFN-γ Sekretion 
stimulierten. Im Gegensatz dazu wurde die funktionelle Reifung von DC, die mit virulentem 
VZV infiziert waren, geblockt. Dieser Effekt war unabhängig vom Genotyp des verwendeten 
VZV-Stammes. Folglich wurde kein bioaktives IL-12 sezerniert, welches als entscheidendes 
Cytokin zum Aufbau einer antiviralen TH1 Immunantwort beiträgt. Darüber hinaus konnte 
gezeigt werden, dass virulentes VZV die Signalkaskade des Toll-like Rezeptors 2 (TLR2) in DC 
inhibiert und somit die IL-12 Produktion verhindert. Demzufolge wurde die IFN-γ Sekretion 
von γδ T-Zellen verhindert. 
In der vorliegenden Arbeit wurde eine neue Immunevasionsstrategie virulenter VZV 
Stämme entdeckt, welche erklären könnte, wie virulente VZV Stämme frühe antivirale Im-
munantworten umgehen und somit erfolgreich in der Haut replizieren. Zusätzlich konnte 
gezeigt werden, dass Kandidaten für Vakzinierungsstrategien nicht mit der Instruktion von 
DC interferieren sollten, um die Stimulation adaptiver Immunantworten zu gewährleisten. 
Daher könnten die gewonnen Erkenntnisse einen wichtigen Beitrag zur Entwicklung zu-
künftiger Vakzinierungsstrategien leisten.  
4 
Summary 
 
Varicella-zoster virus (VZV) which belongs to the family of herpesviruses is restricted to 
humans and distributed worldwide. The seroprevalence is over 95%. Primary infection of 
VZV causes chickenpox, a typical childhood disease characterized by fever and dissemi-
nated rash. Thereafter, VZV establishes a lifelong latency within sensory ganglia and can be 
reactivated to cause herpes zoster. This disease is characterized by lesions confined mostly 
to a single dermatome. A frequent complication of herpes zoster is the painful postherpetic 
neuralgia. Since 1995 the attenuated strain V-Oka of VZV is successfully used as vaccine in 
the United States of America to immunize children against VZV infection. In 2004 the vac-
cine was also licensed for Germany. In contrast to infection by circulating virulent VZV 
strains, vaccination with V-Oka remains asymptomatic. T cell mediated immunity is impor-
tant to resolve VZV infection and an age related decline in VZV specific T cell mediated im-
munity is correlated with an increase of the incidence for herpes zoster and postherpetic 
neuralgia.  
The skin is the major replication site of VZV and immunological differences between 
virulent VZV and the vaccine should become most apparent within this immune organ. 
However, these differences have not been elucidated so far. Cutaneous immune cells com-
prising epidermal Langerhans cells (LCs), dermal dendritic cells (DDCs), inflammatory den-
dritic cells and intraepithelial γδ T cells contribute to the induction of effective antiviral 
immune responses. Thus, the major focus of this study was to highlight cutaneous immune 
responses to virulent VZV strains as compared to the vaccine. Therefore, clinical isolates of 
circulating VZV genotypes in Europe were included in this study. 
In this study the disappearance of LCs in skin lesions of herpes zoster patients was 
observed. In contrast, a strong infiltration of myeloid-derived inflammatory DCs has been 
detected. Furthermore, it has been shown for the first time that ex vivo isolated LCs and 
DDCs were permissive for VZV infection. Most importantly, no differences between the 
effects of the vaccine strain V-Oka and a virulent VZV strain have been observed. In vitro 
studies with monocyte-derived dendritic cells (DCs), reflecting inflammatory DCs, showed 
that they were efficiently infected by both, the vaccine and a virulent VZV strain. Intriguing-
ly, a significant upregulation of CD1c molecules on VZV-infected DCs was observed. Func-
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tional investigations using intraepithelial CD1c-restricted γδ T cells revealed that DCs in-
fected with the vaccine virus were fully instructed to mature, thereby promoting IFN-γ se-
cretion of γδ T cells. In striking contrast, DCs infected with virulent VZV strains regardless of 
the virus genotype were efficiently blocked to mature functionally. In detail, they did not 
secrete bioactive IL-12 which is an instrumental cytokine for generation of antiviral TH1 
responses. Moreover, virulent VZV blocked Toll-like receptor 2 (TLR2) signaling in DCs the-
reby preventing production of bioactive IL-12 which in turn inhibited IFN-γ secretion by γδ 
T cells. 
In summary, this study discovered a new immune evasion strategy of virulent VZV 
strains which might explain how virulent VZV strains overcome innate antiviral responses 
and successfully replicate within the skin thereby causing the typical rash. Moreover, the 
findings underline that candidate vaccines should not impair DC instruction in order to 
allow stimulation of powerful adaptive immune responses. Therefore, this study might 
have further implication for future vaccine design. 
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Abbreviations 
 
γδ Gamma delta 
APC Antigen presenting cell 
CD Cluster of Differentiation 
cDC Conventional dendritic cell 
CPE Cytopathic effect 
CTL Cytotoxic T cell 
d Days 
DAPI 4′,6-Diamidino-2-phenylindol 
DC Dendritic cell 
DC-SIGN Dendritic cell-specific intercellular adhesion molecule-3-grabbing 
non-integrin 
DDC Dermal dendritic cell 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acid  
ds Double-stranded 
EDTA Ethylenediaminetetraacetic acid 
ELISA Enzyme linked immunosorbant assay 
EMEM Eagle's Minimal Essential Medium 
ER Endoplasmatic reticulum 
ERK Extracellular signal-regulated kinase 
FACS Fluorescent-activated cell sorting 
FcR Fc receptor 
FCS Fetal calf serum 
FITC Fluorescein Isothyocyanate 
g Centrifugal force 
gC Glycoprotein C 
gE Glycoprotein E 
GM-CSF Granulocyte-macrophage colony-stimulating factor 
h Hour 
HCMV Human cytomegalovirus 
HELF Human embryonal lung fibrolasts 
HIV-1 Human immunodeficiency virus type 1 
HRP Horseradish peroxidase 
HSV Herpes-simplex virus 
Hu Human 
HZ Herpes zoster 
ICAM-1 Intercellular adhesion molecule 1 
iDC Immature dendritic cell 
IDE Insulin degrading enzyme 
IFN Interferon 
IFN-γ Interferon gamma 
IgG Immunoglobulin G 
IL Interleukin 
IL-12p70 Interleukin 12p70 (bioactive) 
IU International Units 
JNK C-Jun N-terminal kinases 
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JoSt Clinical isolate of VZV 
KSHV Kaposi's sarcoma-associated herpesvirus 
LC Langerhans cell 
LPS Lipopolysaccharide 
LTA Lipoteichoic acid 
MACS Magnetic-activated cell sorting 
MAP kinase Mitogen-associated protein kinase 
mDC Mature dendritic cell 
MFI Mean fluorescence intensity 
MHC class I Major histocompatibility complex class I 
MHC class II Major histocompatibility complex class II 
min Minute 
MOI Multiplicity of infection 
mRNA Messenger RNA 
NK cell Natural killer cell 
NKT cell Natural killer T cell 
ORF Open reading frame 
p.i. Post infection 
PAMP Pathogen-associated molecular pattern 
PBMC Peripheral blood mononuclear cell 
PBS Phosphate buffered saline 
pDC Plasmacytoid dendritic cell 
PE Phycoerythrin 
PFU Plaque forming unit 
PHA Phytohaemagglutinin 
PHN Postherpetic neuralgia 
PI Propidium iodide 
PRR Pattern recognition receptor 
RNA Ribonucleic acid 
RPMI Roswell Park Memorial Institute medium 
RT Room temperature 
RT-PCR Reverse transcriptase-polymerase chain reaction 
SCID Severe combined Immunodeficiency 
SD Standard deviation  
SDS-PAGE Sodium dodecyl sulphate-polyacrylamide gel electrophorese 
STAT Signal transducer of activation and transcription 
TAP Transporter associated with antigen processing 
TCR T cell receptor 
TH1 CD4
+
 T helper cell, producing type-1 cytokines (IL-2, IFN-γ) 
TH17 CD4
+ 
T helper cell, producing IL- 17 
TH2 CD4
+
T helper cell, producing type- 2 cytokines (IL-4, IL-5 and IL-13) 
TLR Toll-like receptor 
TMB 3,3’,5,5’-Tetramethylbenzidine 
TNF-α Tumor necrosis factor-α 
U Units 
V-Oka Vaccine strain V-Oka 
VZV Varicella-zoster virus 
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1 Introduction 
 
1.1 Varicella-Zoster Virus (VZV) 
 
Varicella-zoster virus belongs to the family Herpesviridae and its geographic distribution is 
worldwide
1
. In Germany the seroprevalence reaches nearly 95%. The human being is the 
only reservoir of VZV.  
The virion measures 180 to 200 nm in diameter and is composed of an outer lipid 
membrane which harbors the five glycoproteins (gp) gpI (gE), gpII (gB), gpIII (gH), gpIV (gI), 
gpV (gC), the tegument containing viral proteins of mostly unknown function, followed by 
the capsid where the linear double-stranded viral DNA of ∼125 kbp encoding for ∼71 open 
reading frames (ORFs) is located
2,3
.  
 
Fig. 1: Morphology and structure of VZV.  
(a) Scheme of the virion. Within the outer membrane the glycoproteins gE, gB, gH, gI and gC are anc-
hored. The tegument contains viral proteins and the nucleocapsid which harbors the linear double-
stranded (ds) DNA. www.bio.davidson.edu (b) Electronic microscopy of VZV virion (showing the viral 
DNA surrounded by the capsid, embedded within the tegument and enveloped by the outer viral mem-
brane containing the viral glycoproteins)
4
. 
VZV binds with the glycoproteins gB, gH and gI to heparine sulfate on the cell sur-
face, attaches to mannose 6-phosphate receptor and interacts through glycoprotein gE 
with the insulin degrading enzyme (IDE) to enter the host cell
4-6
. After fusion of the viral 
membrane with the host cell membrane the capsid is released into the cytoplasm and is 
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transported through actin and microtubules to the nuclear pore complex where the DNA is 
injected into the nucleus
7
. In the nucleus viral genes are transcribed in a cascade-like man-
ner beginning with the immediate early (IE) genes, followed by the early (E) genes and fi-
nally the late (L) genes. Viral DNA is replicated by the rolling circle mechanism in the nuc-
leus and the cleaved concatemers are packaged into pre-formed viral capsids. After 
budding from the inner nuclear membrane to the rough endoplasmatic reticulum (rER) and 
into the cytoplasm the assembly of the virions takes place at the trans-golgi network (TGN). 
After wrapping of the TGN membrane the double-enveloped virions fuse with the cellular 
plasma membrane and release enveloped virions. 
Despite the fact that VZV found in the pustular vesicles of VZV patients is highly con-
tagious, VZV is highly cell-associated in vitro and no cell-free infectious virus is released 
into the cell culture
8
. This phenomenon is explained by the fact that pre-formed virions are 
directed to the endosomal compartment due to the presence of mannose 6-phosphate 
receptor where the low pH induces degradation of the viral glycoproteins
4
.  
 
1.2 VZV Pathogenesis 
 
Due to the fact that the replication cycle of VZV is restricted to human cells or tissues and 
its highly cell-associated nature, only little is known about its pathogenesis compared to 
other human herpesviruses like for example herpes simplex virus type-1 (HSV-1). To study 
the pathogenesis of VZV in vivo the severe combined immunodeficient (scid/scid) mice 
transplanted with human thymus/liver (T cell) or human skin xenografts known as SCID-
human implant mouse model is used
9
.  
Primary infection of naive persons leads to chickenpox which is a typical childhood 
disease and is characterized by a disseminated rash (Fig. 2a). Varicella is generally a mild 
illness; however, serious and occasionally fatal complications occur particularly in adults or 
immunocompromised people
10-13,13
. Encephalitis and fulminant hepatitis are the most se-
vere manifestations caused by VZV
13-15
. Also children with apparently normal immune 
functions can have severe life-threatening complications due to varicella for yet unknown 
reason
16
. 
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After primary infection the virus establishes latency in sensory ganglia and can be 
reactivated to cause herpes zoster which is characterized by a rash, mostly restricted to a 
single dermatome (Fig. 2b)
17
. A severe complication of herpes zoster is the development of 
the very painful postherpetic neuralgia (PHN)
18
. The incidence for herpes zoster climbs 
steadily with increasing age and is believed to correlate with declining cell-mediated im-
munity to VZV
19
. 
 
Fig. 2: Clinical signs of chickenpox and herpes zoster.  
(a) Disseminated rash of a child after primary infection with a virulent strain of VZV. (b) Herpes zoster 
with a unilateral rash restricted to a single dermatome after reactivation of VZV. www.online-praxis.com 
In the course of VZV transmission, naive persons inhale infectious virus present in 
aerosols or droplets of VZV-infected persons. After reaching the upper respiratory tract it is 
assumed that the virus infects dendritic cells (DCs) of the respiratory mucosa which trans-
port the virus to local lymph nodes where the transmission to T cells occurs (Fig. 3)
20
. In 
the SCIDhu mouse model it could be demonstrated that VZV posses tropism for CD4
+
 and 
CD8
+
 T cells
9
. Additionally, this tropism could be linked to the viral protein kinases open 
reading frame 47 (ORF47) and ORF66
21
. VZV infects preferentially tonsillar CD4
+
 T cells 
which express activation, memory and skin homing markers
22
. In a primary viremia the 
virus is transported by peripheral blood mononuclear cells (PBMCs) to the replication sites 
liver and spleen
2,23,24
. In a second viremic phase the virus reaches the skin, the major repli-
cation site of VZV. The time from beginning of infection until the appearance of the typical 
rash is 10 to 21 days. During this prolonged incubation period the virus must circumvent 
13 
immune recognition to prevent its elimination by immune effector mechanisms of the 
host.  
 
Fig. 3: Pathogenesis of VZV.  
(a) Droplets containing infectious virions from infected person can be inhaled by naive persons. The virus 
replicates within regional lymph nodes and is transported cell-associated in a first viremia to liver and 
spleen. After a second viremia the virus is transported to the major replication site the skin. Acute illness 
is characterized by a disseminated rash with vesicles containing infectious virions. The virus establishes 
latency within dorsal root ganglia.
2
 (b) It is assumed that the virus infects dendritic cells (DCs) of the 
respiratory mucosa which transport the virus to the local draining lymph nodes. There, the virus is 
transmitted to T cells which transport virions during a viremic phase to liver, spleen and skin
2,25
.  
 
1.3 Immunity during Primary VZV Infection 
 
Innate immune responses are presumed to mediate the initial control of primary VZV infec-
tion. Patients with deficiency in natural killer (NK) cells or natural killer T (NKT) cells show 
severe forms of varicella infections
11,26,27
. In the SCID-hu mouse model it could be demon-
strated that uninfected epidermal cells of the skin surrounding the VZV vesicle secreted 
large amounts of interferon (IFN)-α whereas IFN-α secretion was inhibited in VZV-infected 
epithelial cells
28
.  
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Adaptive T cell responses appear to be critical for resolving primary infections and to 
control viral reactivation
29
. Interestingly, VZV specific T cell immunity is not detected till the 
onset of the rash, suggesting effective immune evasion mechanism in the initial phase of 
infection. A delay of VZV specific T cell immunity is correlated with life-threatening disse-
mination of the virus. The majority of epitopes recognized by the T cell receptor (TCR) on T 
cells and antibodies are derived from the immediate early protein 62 (IE62) and several 
glycoproteins of VZV. For example, cytotoxic CD8
+
 T cells have been shown to recognize 
IE62 and gpI of VZV
30
. Additionally, it could be demonstrated that T cells recognize multiple 
epitopes of IE62 and gpI
31
.  
Immunological memory to VZV is characterized by the persistence of cytotoxic T cells 
responsive to viral tegument and regulatory proteins encoded by ORF4, ORF10, ORF29, 
and ORF62
32
. Persistent high frequencies of VZV ORF4 protein specific CD4
+
 T cell res-
ponses could be detected after primary infection
33
. Recently, it could be demonstrated that 
CD4
+
 T cells directed to gpI maintain rapid effector functions even many decades after pri-
mary infection
34
. Additionally, CD4
+
 T cells specific to IE63 protein of VZV were proposed to 
be important in the control of viral reactivation
35
. 
VZV specific neutralizing antibodies are produced during primary infection but the 
course of infection of varicella appears to be uncomplicated in patients with agammaglobu-
linemia suggesting that the humoral immune response is less important
36
.  
 
1.4 Vaccination and Antiviral Therapy 
 
A live attenuated varicella vaccine was developed by serial passaging of clinical isolate 
“Oka” from a japanese boy suffering from chickenpox
37
. The clinical isolate was passaged in 
cell culture several times using human embryo fibroblasts and guinea-pig embryo fibrob-
lasts. This resulted in the accumulation of numerous mutations. The attenuated vaccine 
strain V-Oka exhibits nucleotide substitutions in several ORFs (48, 51, 52, 55, 56, 58, 59, 60, 
62, 64, and 68) as well as deletions and insertions within certain regions
38,39
. The atte-
nuated vaccine strain V-Oka is commercially produced by the companies Merck (VARIVAX), 
GlaxoSmithKline (Varilrix) and the Biken Institute in Japan (Biken varicella vaccine). The 
vaccine is successfully used since 1995 in the USA and since 2004 in Germany to immunize 
15 
children against varicella
40
. The vaccine induces protective immune responses through the 
induction of specific CD4
+
 and CD8
+
 T cells as well as neutralizing antibodies
41,42
. Neverthe-
less, in up to 5% of the healthy children vaccination causes a varicella-like rash but symp-
toms are milder and fewer vesicles occur. It could be demonstrated that vaccine prepara-
tions contain a mixture of VZV strains and that lesions from varicella-like rashes or herpes 
zoster contain only a single clone of VZV suggesting selection of a single strain during pa-
thogensesis
43,44
. The majority of breakthrough varicella in immunocompetent vaccinees 
was linked to simultaneous infection with circulating virulent VZV strains
45
. Nevertheless, 
LaRussa et al. demonstrated in this study that the vaccine strain has the capacity to reacti-
vate and cause herpes zoster in immunocompetent vaccines. Despite its potential for reac-
tivation, a study on children with leukemia could demonstrate that immunization with the 
vaccine decreased the incidence for herpes zoster compared to infections with virulent VZV 
strains in this study group
46
. Recently, in a long term follow-up study, the incidence for 
herpes zoster in vaccinated young adults was similar to published data for the US popula-
tion in the pre-vaccine era
47
. This suggests that despite its potential to reactivate the vac-
cine is efficiently controlled by yet unknown immune effector mechanisms within vacci-
nated population. Due to massive vaccination of children, a surveillance of vaccine induced 
complications and breakthrough infections is necessary.  
Now, the vaccine is also tested in promising trial studies to boost the cell-mediated 
immunity of elderly people to decrease the incidence of herpes zoster and PHN
48-50
. This is 
important with respect to the fact that the population in industrialized countries increases 
in age. Additionally, it was shown that frequent exposure to varicella boosts immunity to 
herpes zoster
51,52
. These data were used to parameterize a mathematical model that esti-
mates the impact of varicella vaccination on herpes zoster incidence. This model predicts a 
major epidemic of herpes zoster due to the fact that virulent VZV strains circulate less in 
the young population which might boost cell mediated immunity in the older population. 
This scenario is currently discussed although no follow-up study supports this hypothe-
sis
53,54
.  
For anti-viral therapy, the synthetic nucleoside analogues acyclovir, famcyclovir, vala-
cyclovir or brivudine are commonly used
55,56
. It is important to treat patients within 72h 
after the onset of the rash to accelerate crusting of the lesions, to promote resolution of 
16 
acute pain, to diminish the risk of cutaneous and visceral complications and to prevent 
PHN or shorten the duration of zoster-associated pain
57
.   
 
1.5 Dendritic Cells: Linking Innate with Adaptive Immunity 
 
Dendritic cells (DCs) are a special subset of antigen presenting cells (APCs) which are uni-
quely positioned at the interface between the environment and epithelial surfaces such as 
the skin and the mucosa of digestive, respiratory and reproductive tracts
58,59
. They play an 
important role in both the induction of self tolerance and the priming of adaptive immune 
responses. For this purpose they appear in two different stages according to their pheno-
typic and functional properties: as immature DCs (iDCs) or as mature DCs (mDCs) (Fig. 
4)
60,61
.  
This differentiation process is induced in response to microbial or viral products, 
lymphocytes, cytokines, endogenous ligands or immune complexes
62
. To sense pathogen-
associated molecular pattern (PAMP) iDCs express a set of innate pattern recognition re-
ceptors (PRRs) like the Toll-like receptors (TLRs), the retinoic-acid-inducible gene I (RIG-I) 
and melanoma differentiation-associated gene 5 (MDA5)
63-65
. Stimulation of PRRs induces 
the activation of intracellular signaling pathways and altered gene expression. TLRs, RIG-I 
and MDA5 have emerged as key sensors in recognizing viral components like nucleic acid 
and structural proteins produced during viral replication or viral entry and penetration
66,67
. 
Activation of PRRs leads to subsequent DC maturation. However, it becomes evident that 
triggering of multiple PRRs is needed to induce functional maturation of DCs, in particularly 
marked for the production of the immune-regulating cytokine IL-12
68-70
. Additionally, it 
could be demonstrated that lymphocytes like NK cells, natural killer T (NKT) cells, conven-
tional αβ T cells and γδ T cells can induce the maturation of iDCs
71-73
. Besides endogenous 
ligands like heat shock proteins also immune complexes through the binding to Fc recep-
tors (FcRs) on iDCs can trigger maturation
74
. 
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Fig. 4: Dendritic cell maturation model.  
Dendritic cells (DCs) in the steady state are immature antigen-presenting cells (APCs) that internalize 
exogenous antigens and process them for MHC class II mediated presentation but cannot prime immune 
responses. Signal 1 is delivered through the T cell receptor (TCR) when it engages an appropriate pep-
tide-MHC class complex. Signal 1 alone is thought to promote naive T cell inactivation by anergy, dele-
tion or leading to tolerance. Maturation induced by danger signals leads to an an increase in immuno-
genicity and downregulation of antigen acquisition and antigen-processing ability. Signal 2 is provided by 
co-stimulation through CD28 on the T cell when it engages CD80 and/or CD86 on DC. However, signal 2 is 
likely to be a fine balance between positive and negative co-stimulatory signals emanating from many 
receptors. Signal 1 and 2 induce immunity. Finally, mature DCs can be licensed by T helper (TH) cells or 
other cells e.g. NKT cells and γδ T cells with subsequent induction of TH-cell-dependant cytotoxic T lym-
phocyte (CTL) responses. Scheme of C. Reis e Sousa, 2006
61
, modified. 
The main feature of iDCs in peripheral tissues is their capacity to capture and process 
antigens. Therefore, they are well suited to function as sentinels for invading pathogens. 
Sensing of PAMPs by PRRs induces their maturation with the following phenotypic and 
functional changes: up-regulation of MHC class I and II molecules, up-regulation of the co-
stimulatory molecules CD40, CD80 and CD86, expression of CD83 and secretion of cyto-
kines such as tumor necrosis factor-α (TNF-α), interleukin-12 (IL-12), IL-10, interferon-α 
(IFN-α), IFN-β and IFN-γ
75-77
. The types of cytokines produced depend on the DC subset as 
well as the activation stimulus. Another important aspect of the maturation process is the 
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change in the repertoire of chemokine receptors and the secretion of chemokines which 
result in different migration behavior
78,79
. Mature DCs migrate to local lymph nodes where 
they interact with naive T cells and B cells
80
. Due to the up-regulation of antigen presenting 
and co-stimulatory molecules on their cell surface, mDCs gain the capacity to stimulate 
efficiently naive and memory T cells and B cells and consequently initiate powerful adap-
tive immune responses. Mature DCs can trigger the activation of CD8
+
 T cells by antigen 
presentation on MHC class I molecules whereas the T cell receptor (TCR)/CD3 complex of 
CD4
+
 T cells recognizes peptides presented on MHC class II molecules
81
. Additional ligation 
of CD28 on T cells with the co-stimulatory molecules CD80 and CD86 on mDCs license the 
CD8
+
 or CD4
+
 T cells to gain full effector functions
82
. Activated CD8
+
 cytotoxic T lympho-
cytes (CTLs) induce apoptosis through Fas ligand (FasL) in cells infected with intracellular 
pathogens like viruses. Furthermore, CTLs release perforin and granulysin from intracellular 
stored granules to form pores in the membrane of infected target cells
83
. Mature DCs can 
induce different types of CD4
+ 
helper T cells (TH cells), such as TH1, TH2, TH17 or regulatory T 
cells (Treg), depending on the secreted cytokine profile
84,84
. Secretion of IL-12 by mDCs 
drives the differentiation of T helper cells into TH1 cells which gain the capacity to produce 
IL-2, IFN-γ and TNF-α. The latter`s in turn activate macrophages, rendering them resistant 
to infection, and activate NK cells. Importantly, secretion of IL-12 by DCs and IFN-γ by TH1 
cells is regulated via positive feedback
85
. TH2 cells are characterized by their secretion of IL-
4, IL-5, IL-13 and IL-25 which in turn induce the proliferation of B cells and their antibody 
class switching. The driving of T helper cells into the TH2 direction is associated with resis-
tance to extracellular parasites like helminthes and the induction of allergic diseases. Im-
mature DCs have been shown to induce secretion of the suppressive cytokine IL-10 by CD4
+
 
regulatory T cells
86
. Regulatory T cells play an important role in maintaining self-tolerance 
as well as in regulating immune responses. Recently, it has been demonstrated that mDCs 
secreting IL-6, TNF-α and IL-23 instructed CD4
+
 T cells to become IL-17 secreting T helper 
cells (TH17 cells)
87
. TH17 cells play an important role in autoimmune diseases and mediate 
protective immunity to extracellular bacteria and fungi
88
. 
DCs are key players of the innate immune system which drives adaptive immune res-
ponses into a certain direction by programming T cells. The dialogue between DCs and T 
cells is considered as a three signal integration model: Signal 1 comprising the engagement 
of specific peptid/lipid through MHC class I, II /CD1 molecules with the TCR/CD3 complex; 
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Signal 2 provides the co-stimulatory molecules CD80 and CD86 for engagement of CD28  
on the T cell; and finally Signal 3 is the cytokine secreted by the DCs which determine the 
differentiation of the T cell into an effector T cell (CTL, TH1, TH2, TH17 or Treg)
61,89
. 
 
1.6 Subsets of Dendritic Cells 
 
Broadly, DCs can be divided into distinct subsets, each with specific markers and functions: 
plasmacytoid DCs (pDCs), conventional DCs (cDCs) and interferon-producing killer DCs 
(IKDCs).  
Plasmacytoid DCs or interferon (IFN)-producing cells, are characterized by their abili-
ty to secrete rapidly large amounts of type I interferons (IFNs), IFN-α and IFN-β, in re-
sponse to stimulation by pathogens like viruses
90,91
.  
Conventional DCs (cDCs) of myeloid origin can be phenotypcially distinguished from 
pDCs as they express CD11c on their cell surface
92
. Conventional DCs can be further sub-
divided into three major DC populations: migratory DCs, resident DCs and monocyte-
derived or inflammatory DCs
93
. Migratory DCs act as sentinels in peripheral tissues and 
migrate after uptake of antigens to local lymph nodes through lymphatics where they 
present these antigens to resident T and B cells
94
. Langerhans cells (LCs) and dermal DCs 
(DDCs) are examples for migratory DCs. In contrast lymphoid tissue resident DCs do not 
migrate through the lymph and their function and life-history are restricted to one lympho-
id organ. They sample and present self and foreign antigens in that lymphoid organ. Exam-
ples include thymic and splenic cDCs. Migratory and tissue resident DCs are normally 
present during steady state conditions. In strong contrast, inflammatory DCs appear as a 
consequence of inflammation or stimuli through pathogens. They can arise from myeloid 
and lymphoid precursors
95
. Recently, it has been demonstrated that inflammatory DCs de-
rived from monocytes control the induction of protective TH1 responses during Leishmania 
infection
96
.  
Recently, IKDCs have been discovered which share phenotypic and functional proper-
ties of DCs and natural killer (NK) cells
97
. They produce substantial levels of type I interfe-
ron, IL-12 and IFN-γ, depending on activation stimuli. By losing their NK cell like cytotoxic 
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potential they gain DC like antigen presenting activity and upregulate MHC class II and co-
stimulatory molecules. 
 
1.7 Dendritic Cells of the Skin and the Induction of Viral Immune Response 
 
The skin, the largest organ of the human body is comprised of distinct compartments rele-
vant to its immune function. The epidermis, the most superficial layer, functions as physical 
barrier and is composed of keratinocytes, intraepithelial lymphoctyes and specialized DCs 
so called Langerhans cells (LCs)
98
. The dermis is mainly composed of dermal fibroblasts and 
immune cells including dermal DCs (DDCs), mast cells and a small number of cutaneous 
lymphocyte antigen (CLA)-positive memory T cells (Fig. 5a).  
Migratory cDCs in the steady state of the skin comprise immature epidermal LCs and 
immature DDCs which function as sentinels for invading pathogens
99
. LCs of the epidermis 
are characterized by expression of Langerin and CD1a, which function for non-peptide an-
tigen presentation
100,101
. DDCs of the dermis express the mannose receptor (CD206) and 
DC-SIGN (CD209) for internalization of glycolipids and their sorting into the endocytotic 
pathway
102,103
.  
Sensing of pathogens leads to release of cytokines and activation of epidermal cells, 
keratinocytes and cutaneous DCs (Fig. 5b). Activated LCs and DDCs undergo maturation 
and migrate to local lymph node where they present captured antigens to naive and mem-
ory T and B cells. The released cytokines and chemokines by cutaneous cells induce upre-
gulation of E-selectin and ICAM1 which recruits additional innate immune cells from ve-
nules to the inflammed tissue. Since many years there is conflicting data regarding which 
type of dendritic cell, LCs or DDCs, contribute to immunity against viral infections. In the 
last few years several research groups demonstrated that migratory DDCs efficiently 
present antigens to lymph node resident T cells, therefore contributing to cutaneous im-
munity to viral infections, especially for herpesviral infections
104-106
. Which type of dendritic 
cell contributes to cutanous VZV immunity has still to be elucidated even though a role for 
pDCs during varicella was recently discussed
107
. Furthermore, in skin sections from varicella 
and herpes zoster patients the absence of intercellular adhesions molecule-1 (ICAM-1) 
expression on VZV-infected keratinocytes was observed. ICAM-1 serves as adhesion mole-
21 
cule for lymphocyte function-associated antigen 1 (LFA-1) bearing T cells 
108
. However, VZV 
certainly has further evasion strategies to ensure its replication and transmission within 
this organ. 
 
 
Fig. 5: Immune surveillance in the skin.  
(a) Immune response in non-inflammed skin. The human skin is composed of three distinct compart-
ments according to their immune function: epidermis, dermis and dermal post-capillary venules. Within 
the steady state the epidermis, as physical barrier, is composed amongst others of keratinocytes, Langer-
hans cells (LCs) and intraepithelial lymphocytes. The dermis is mainly composed of dermal fibroblasts, 
dermal DCs (DDCs) and a small number of cutaneous lymphocyte antigen (CLA)-positive memory T cells. 
Dermal post-capillary venules express low levels of E-selectin, CC-chemokine ligand 17 (CCL17) and inter-
cellular adhesion molecule 1 (ICAM1). These support the emigration of CLA
+
 memory T cells. (b) Immune 
response in inflamed skin. Pathogen invasion leads to release of primary cytokines and activation of 
epidermal cells, keratinocytes, LCs and DDCs. Activated LCs and DDCs mature and emigrate from the 
tissue to local lymph node, carrying antigen for presentation to naive and memory T cells. Released cyto-
kines and chemokines induce upregulation of E-selectin and ICAM1 thereby directing the recruitment of 
additional innate immune cells.
98
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1.8 Herpesviral Interference with DC Maturation and Function 
 
For a variety of viruses including herpes simplex virus type -1 (HSV-1), herpes simplex type-
2 (HSV-2), human cytomegalovirus (HCMV) and VZV it was shown that they can infect DCs 
and inhibit their immune function
20,25,109,110
. Viral infection hijacks the biosynthetic machi-
nery of the host cell and ensures the rapid synthesis of viral proteins, thereby providing a 
reservoir for viral peptides that are loaded on MHC molecules. To ensure its replication and 
spread viruses have evolved several evasion strategies to circumvent immune recognition. 
The IE protein ICP-47 of HSV-1 blocks the transporter associated with antigen processing 
(TAP) within the membrane of the endoplasmatic reticulum (ER) and prevents CTL recogni-
tion through MHC class I molecules
111,112
. Moreover, HSV-1 interferes with the maturation 
of DCs by inhibiting upregulation of co-stimulatory molecules, cytokine secretion and res-
ponsiveness to chemokines required for migration to lymphoid organs
113
. Recently, it has 
been demonstrated that HSV-1 induces rapid induction of apoptosis in iDCs
114
. Further-
more, HSV-1 inhibits TCR signaling within T cells exposed to infected cells 
115
. HSV-2 infec-
tion of murine DCs induces rapid cell death and their functional impairment
116
. The largest 
human herpesvirus HCMV also encodes for two viral proteins, US2 and US11, which inhibits 
MHC class I presentation and encodes for a viral IL-10 homologue that interferes with the 
function and survival of DCs
109,110
. 
Recently it was shown that VZV can productively infect iDCs, but infection did not in-
duce any phenotypical changes compared to mock-infected iDCs
20
. The viral protein kinase 
encoded by ORF47 was shown to be critical for viral replication in iDCs
117
. Furthermore, it 
could be demonstrated that VZV was transmitted from infected iDCs to T cells which might 
transport the virus through the blood stream to the replication sites liver, spleen and finally 
the skin
20
. In contrast, productive infection of mDCs induces subsequent phenotypical and 
functional changes: downregulation of cell surface expression of MHC class I, CD80, CD86 
and CD83 but not of MHC class II molecules and reduced ability to stimulate allogeneic T 
cell proliferation
118
. It has to be mentioned that the described observations in both studies 
were made only with a clinical isolate of VZV (circulating in the USA) and were not com-
pared to the vaccine response.  
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1.9 Immune Evasion Mechanisms of VZV 
 
It could be demonstrated that VZV interferes with the classical antigen presentation 
through MHC class I and II molecules. The serine /threonine protein kinase ORF66 of VZV 
has been shown to be responsible for the retention of MHC class I molecules within the 
golgi compartment
119-121
. Moreover, VZV inhibits IFN-γ-mediated induction of cell surface 
MHC class II expression on infected fibroblasts
122
. Recently, the interference of VZV with 
the activation of nuclear factor-κ B (NF-κB) has been demonstrated in vitro and in human 
epidermal cells in vivo
123
.  
 
1.10 CD1 Antigen Presentation 
 
Besides the classical antigen presentation of peptides through MHC class I and II molecules 
a second antigen presentation system exists. CD1 molecules present lipids to CD1 restricted 
T cells
124
.  In humans the CD1 gene complex is encoded on chromosome 1
125
. Human ex-
press five CD1 isoforms which are divided into group 1 including CD1a, CD1b and CD1c and 
group 2 solely comprising CD1d. Besides these cell surface expressed CD1 molecules which 
recirculate within endocytotic compartments, CD1e belonging to group 3 is exclusively 
expressed intracellularly (Fig. 6)
126
. 
Group 1 CD1 molecules are mainly found on professional APCs, whereas CD1d is 
more widely expressed. In vitro CD1a, CD1b and CD1c molecules can be detected at high 
amounts on monocyte derived DCs.  
Like MHC class I molecules, all CD1 molecules are heterodimers composed of an al-
pha chain and non-covalently linked ß2 microglobulin (ß2m). CD1 molecules can present 
foreign, self and synthetic glycolipids to CD1-restricted T cells
127
. It was shown that isopre-
noid glycolipids of the outer cell wall of Mycobacterium tuberculosis was recognized by 
CD1c restricted T cells
128,129
.  Recently, it was shown that CD1-restricted T cells have a dual 
reactivity for both self and foreign lipid antigens
130
. Interestingly, recognition of self lipids 
presented through CD1 molecules was recently also demonstrated for γδ T cells
131
.  
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Fig. 6: Trafficking of human CD1 molecules.  
Top left: CD1a molecules are transported in association with ß2 microglobulin (ß2m) from the endo-
plasmatic reticulum (ER) through the secretory pathway to the plasma membrane (PM). CD1a spontane-
ously internalizes via clathrin-coated vesicles and recycles through early/sorting and early/recycling en-
dosomes (EE/ER) to the PM. Top right: The cellular trafficking of CD1b and CD1d is very similar. After 
transport to the PM, their endoyctosis into clathrin-coated pits is mediated through the interaction of 
their cytoplasmic tails with the cytosolic adaptor complex (AP)-2. They are delivered to early endosomes, 
where they access late endsomes (LE), lysosomes and the MHC class II compartments (MIIC/Lys) through 
their interaction with cytosolic adaptor AP-3. Bottom left: CD1c molecules are internalized via clathrin-
coated vesicles through their interaction with AP-2. Most of the CD1c molecules recycle to the cell sur-
face through EE/ER but a small fraction can be detected within LE. Bottom right: CD1e molecules remain 
intracellularly. In iDCs most CD1e molecules are present in the Golgi. After activation and maturation of 
DCs, CD1e molecules accumulate in LE and lysosomes.
132
 
In the recent years it was shown that antigen presentation through CD1 molecules is 
correlated with the outcome of several diseases. It could be demonstrated that expression 
of group 1 CD1 molecules was strongly induced in skin lesions of patients with the tubercu-
loid form of leprosy, showing active cellular immunity to infection. In strong contrast, pa-
tients with the lepromatous form did not show induction of CD1 proteins in skin lesions 
and lacked effective cell-mediated immunity
133
. Additionally, antigen presentation through 
25 
CD1a and CD1c molecules was also shown to be involved in some human autoimmune 
disorders
134
. Intriguingly, a patient who was vaccinated against VZV and developed a dis-
seminated varicella had a deficiency in NKT cells
26
. This case report gives evidence that CD1 
antigen presentation plays a role in VZV pathogenesis. 
 
1.11 Viral Interference with CD1 Antigen Presentation 
 
Several strategies to evade CD1 antigen presentation have been elucidated for members of 
the Herpesviridae. Recently, it was shown that HSV-1 interferes with the recirculation of 
CD1d molecules in APCs therefore inhibiting recognition by NKT cells
135,136
. For Kaposi sar-
coma-associated herpesvirus (KSHV) two modulator of immune recognition (MIR) proteins 
were identified which blunt CD1d antigen presentation by accelerating endocytosis
137
. In-
terference with the CD1b antigen presentation on professional APCs was recently hig-
hlighted for HCMV
138
. Furthermore, the nef protein of human immunodeficiency virus-1 
(HIV-1) blocks lipid antigen presentation by increasing the internalization of CD1d mole-
cules from the cell surface and retaining them in the golgi compartment
139
. 
 
1.12 γδ T Cells 
 
Gamma delta (γδ) T cells represent a small subset of T cells that together with conventional 
αβ T cells and B cells use somatic DNA rearrangement to assemble the genes encoding for 
their defining antigen receptor. The structure of the T cell receptor (TCR) of γδ T cells is 
composed of a heterodimer consisting of γ and δ chain. The chains are arranged by variable 
(V), diversity (D), junctional (J) and constant (C) gene segments. There appear to exist only 
six functional Vγ genes in humans, five in the Vγ1 family and another more distantly related 
Vγ2 gene and ∼8-10 distinct Vδ genes
140
. Despite this limited combinatorial diversity com-
pared to conventional αβ-TCR the repertoire of γδ-TCR is greatly enhanced due to exten-
sive junctional diversity by removal or addition of non-germline-encoded nucleotides at V-
D-J junctions and alternative D segment reading frames. In contrast to αβ T cells which are 
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credited with immunological memory it is not known if γδ T cells carry antigen-specific 
memory despite expression of a memory phenotype different from CD8
+
 αβ T cells
141
.  
In humans there are two major subsets of γδ T cells which differ in their tissue distri-
bution
142
. The major circulating pool of γδ T cells in human peripheral blood expresses 
Vγ9Vδ2 TCR chains (1% to 5%)
143
. These cells have been shown to recognize nonpeptide 
prenyl pyrophosphate intermediates in isoprenoid biosynthesis, aminobisphosphates and 
alkyl amines
141,144
.  Vγ9Vδ2 T cells play an important role in immunity to both bacteria and 
parasites like Mycobacterium tuberculosis and Plasmodium falciparum
145,146
. Additionally, 
this γδ T cell subset has been demonstrated to kill in vitro many types of tumor cells 
through both TCR-mediated and NK receptor-mediated recognition
147
. Prenyl pyrophos-
phates are directly presented to Vγ9Vδ2 T cells, whereas recognition of bisphosphonates 
requires antigen presentation by APCs
141
. Nevertheless, activation of Vγ9Vδ2 T cells re-
quires contact with each other or an APC.  
In contrast, the majority of γδ T cells in human epithelial tissue is represented by the 
subset expressing Vδ1 TCR chains
148,149
. Especially, the dermis of human skin contains Vδ1
+ 
γδ T cells which express receptors for homing to non inflamed skin
150
. In γδ T cell deficient 
mice, it could be demonstrated that skin γδ T cells provide local, nonredundant regulation 
of cutaneous inflammation
151
. It has been demonstrated that Vδ1
+ 
γδ T cells recognize 
stress induced MHC class I-related chain A (MICA) molecule and MICB on cells
152,153
. Re-
cently, recognition of exogenous and self antigens through CD1 molecules by Vδ1
+
 γδ T 
cells was shown
131,154,155
. Furthermore, activation and expansion of Vδ1
+ 
γδ T cells in re-
sponse to lipid extracts of Gram-negative bacteria in the presence of iDCs has been 
shown
156
. The expansion of this γδ T cell subset within the periphery has also been found in 
HIV positive patients and in transplant recipients after infection with HCMV
157,158
. Activated 
Vδ1
+ 
γδ T cells are characterized by their immediate effector functions such as perforin-and 
Fas-mediated cytotoxicity and TH1-type cytokine secretion
131
.  
Intriguingly, γδ T cells display principal characteristics of APCs by processing and pre-
senting antigens as well as providing co-stimulatory signals to αβ T cells
159
. Recently, 
processing and cross-presentation of microbial and tumour antigens by human Vδ2
+
 γδ T 
cells to CD8
+
 αβ T cells could be demonstrated with implication for further exploration in 
immunotherapy research
160
. 
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γδ T cells interact with a variety of immune cells including DCs
161
. The cross-talk of 
DCs and γδ T cells has been shown to link innate with adaptive immune responses during 
microbial and viral infections
162,163
. γδ T cells play an important role in the induction of im-
munity to Mycobacterium tuberculosis and to certain viruses
164,165
. A protective role of γδ T 
cells in herpesviral infections has been shown in HCMV patients and in mice infected with 
HSV-2
166,167
.  
 
1.13 Objectives of the Study 
 
A main focus of this study was to investigate the interplay of VZV with innate immune cells 
which participate in cutaneous immunity. Little is known about VZV pathogenesis with re-
spect to immune evasion strategies which ensure viral replication and spread within this 
immune organ. Therefore, punch biopsies from papovesicular lesions of immunocompe-
tent herpes zoster patients were analyzed for the presence of immune cells which are in-
volved during VZV pathogenesis. Furthermore, ex vivo isolated cutaneous DCs were tested 
for permissivity to VZV infection and subsequent phenotypic changes.  
Another important aspect of this study was to compare for the first time innate im-
mune responses between the vaccine and clinical isolates of genotypes circulating in Eu-
rope. A key question in this regard was whether the striking differences in the clinical out-
come of infection with circulating rash inducing VZV strains on the one hand and 
asymptomatic infection with the vaccine on the other hand can be explained through in-
nate immune mechanisms. Therefore, the bidirectional crosstalk of DCs and γδ T cells both 
potent initiators of cutaneous immunity was comparatively assessed during infection with 
virulent VZV strains and vaccine, respectively.  
This study provides for the first time evidence that virulent VZV strains regardless of 
their genotype have the intrinsic potential to interfere with the phenotype and function of 
DCs and thereby fail to activate subsequent γδ T cell responses. Thus, this study identifies a 
novel immune evasion mechanism of virulent VZV which might have implications for fur-
ther vaccine design.   
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2 Material and Methods 
 
2.1 Human Samples  
Ethical approval of human samples was granted by the Charité-Universitätsmedizin Berlin eth-
ics committee (EA1/169/06). Healthy control and herpes zoster patients were recruited in coop-
eration with the Department of Dermatology, Venerology and Allergology of the Charité-
Universitätsmedizin Berlin.  
2.1.1 Blood Samples 
10-20 ml of peripheral blood from healthy control and herpes zoster patients were collected 
using a BD Vacutainer (K2E 18.0 mg; REF 367525) blood collection system (BD Bioscience, Hei-
delberg, Germany). Blood was diluted 1:1 with media containing 0.2 mM EDTA and then sepa-
rated by gradient centrifugation on Ficoll-Hypaque (PAA Laboratories, Marburg, Germany) with 
800 g for 30min at room temperature. Peripheral blood mononuclear cells (PBMCs) were col-
lected and stained for the appropriate cell surface markers. 
2.1.2 Isolation of Cutaneous Dendritic Cells  
Human epidermal LCs and DDCs were isolated from abdominal skin or foreskin from healthy 
volunteers. After removal of fat the skin was scaled. With a scalpel the skin was then first cut in 
pieces of 2 cm x 0.5 cm in size and then incised each 1-2 mm to achieve better access for fur-
ther dispase I treatment. Incubation overnight at 4°C in 50 ml of dispase type I (Roche Diagnos-
tics, Mannheim, Germany) at 0.5 mg/ml (10 g skin per 5 mg dispase I) separated the epidermis 
from dermal skin. Thereafter, skin streaks were placed in a petri dish with PBS (w/o Ca
2+
 and 
Mg
2+
) and epidermis was removed from dermis using forceps.  
Epidermal sheets of 30 g skin were incubated in 25 ml of trypsin solution (0.25% trypsin 
in PBS with 5 mM Mg
2+
 and 10 µg/ml DNase (Roche Diagnostics, Mannheim, Germany) and 
incubated for 15min at 37°C, 5% CO2. Trypsin is used to achieve enzymatical cleavage of desmo-
somal cell-cell contacts and DNase I was added to inhibit clumping of cells by released DNA 
from disrupted cells. To remove cells from epidermal sheets the suspension was dispersed with 
a 25 ml pipette until it became unclear. The cell suspension was transferred into a 50 ml falcon 
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tube using a nylon cell filter and addition of 10% FCS stopped trypsin digestion. Cells were re-
covered by centrifugation at 260 g for 15min without break. The cell pellet was resuspended in 
PBS containing 10 µg/ml DNase, 5 mM Mg
2+
 and 10% FCS and incubated for 15min at 37°C with 
readily opened falcon caps. After centrifugation for 5min at 260 g (with break) cells were 
washed twice with PBS containing 10% FCS. LCs were positively isolated from epidermal cell 
suspension using MACS technique and human CD1c (BDCA-1)
+
 Dendritic Cell Isolation Kit  (Mil-
tenyi Biotec, Bergisch-Gladbach, Germany). Therefore, the pellet was resuspended in degassed 
ice cold MACS buffer and anti-CD1c microbeads were added according to manufacturer`s in-
structions and cells were incubated in the refrigerator for 15min. Magnetic separation was 
performed using Large Cell columns. To increase purity of LCs eluted CD1c
+
 fraction was 
enriched over a second Large Cell column. LCs were resuspended with a density of 1x10
6
 
cells/ml in RPMI media containing 10% FCS and GM-CSF (500 IU/ml) and directly centrifuged 
(160g, 45 min, RT) on mock or VZV infected fibroblast monolayers (24-well).  
The dermis was first used by Sven Guhl (Department of Dermatology, Venerology and Al-
lergology of the Charité-Universitätsmedizin Berlin) for isolation of mast cells. Dermis was cut 
using a scissors in very small pieces to increase cellular recovery and decrease incubation time 
for enzymatic digestion. The dermal pulp was incubated in 10 ml/g skin of 37°C pre-warmed 
PBS (Ca
2+
 and Mg
2+
) containing 10% FCS, penicillin/streptomycin (10 000 U/ml), amphotericin B 
(2,5 µg/ml), 5 mM MgSO4, 12 mg collagenase (CellSystem, St. Katharinen, Germany) and 6.5 g 
hyaluronidase type I S (Sigma Aldrich, München, Germany). The suspension was incubated for 
1-1.5h in a 37°C shaking waterbath. Thereafter, cell suspension was transferred in a falcon tube 
using two filters with a pore size of 300 µm (upper filter) and 40 µm (lower filter). The cellular 
filtrate was centrifuged for 15min at 350 g at 4°C the enzyme containing supernatant was re-
transferred to the undigested dermal pulp for a second digestion period in 37°C shaking water-
bath. This was performed for dermal pulp from abdominal skin (enzymatic digestion for two 
times) whereas foreskin was only digested once. The cell pellet was washed twice in PBS (w/o 
Ca
2+
 and Mg
2+
) and once in ice cold degassed MACS buffer by centrifugation at 4°C for 10min 
250 g. Mast cells from dermal suspension were isolated positively using MACS technique and 
the CD117 MicroBead Kit (Miltenyi Biotec, Bergisch-Gladbach, Germany). The dermal cell sus-
pension depleted of mast cells was then used to positively isolate CD1c
+
 DDCs using the MACS 
technique and human CD1c (BDCA-1)
+
 Dendritic Cell Isolation Kit (Miltenyi Biotec, Bergisch-
Gladbach, Germany). The DDCs were isolated as described above for isolation of LCs from epi-
dermal cell suspension. CD1c
+
 DDCs were resuspended with a density of 1x10
6
 cells/ml in RPMI 
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media containing 10% FCS and GM-CSF (500 IU/ml) and directly centrifuged (160 g, 45min, RT) 
on mock or VZV infected fibroblast monolayers (24-well). 
2.1.3 Skin Biopsies 
4 mm punch biopsies of patients with acute herpes zoster (vesicular stage) were taken by Dr. 
med. Martina Ulrich (n=2). Healthy control skin was obtained from patients undergoing breast 
reduction surgery. Specimens were embedded in cryomolds containing tissue freezing medium, 
frozen in isopentane, and stored at –80°C. 5 µm cryosections were performed at -26°C to -27°C 
depending on the content of fatty acids in the skin. Sections were fixed with ice-cold acetone at 
-20°C for 10min and then air-dried at room temperature overnight. For further investigations 
they were stored at -80°C. 
2.2 Cells and Cell Lines 
Tab. 1: Cells and Cell Lines 
Name Source and Characteristic 
HELF Human embryonal lung fibroblasts (Fi301)  
iDCs Human monocyte-derived immature DCs 
γδ T cells
1
 Human CD1c-restricted γδ T cells
131
  
(clone JR.2.28) 
 
CD40L cells
2
 Murine fibroblasts stable transfected with CD40L 
or control plasmid
168
 
1
 kindly provided by Prof. C.T. Morita, University of Iowa College of Medicine, Division of Rheu-
matology, Department of Internal Medicine and Interdisciplinary Graduate Program Immunolo-
gy, Iowa, USA 
2 
kindly provided by Prof. R. Kroczek, Robert Koch-Institut, Berlin, Germany  
2.3 Cell Culture Medium 
BioWhittaker Eagle's Minimal Essential Medium (EMEM) was purchased from Lonza (Verviers, 
Belgium). Roswell Park Memorial Institute 1640 (RPMI 1640) medium, Penicillin/Streptomycin, 
L-Glutamine, Sodium Pyruvate and MEM non essential amino acids were obtained from PAA 
Laboratories (Marburg, Germany). Fetal calf serum (FCS) HyClone from Perbio (Bonn, Germany) 
was heat-inactivated for 30min at 56°C (waterbath) and finally added to the culture medium at 
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a concentration of 10% or 2%. PBS for washing of cells was purchased from PAA Laboratories 
(Marburg, Germany). Adherent cells were collected by tryspinization at a concentration of 
0.05% from Invitrogen (Karlsruhe, Germany).  
 
EMEM or RPMI 1640 medium  
(500 ml) 
 
10% or 2% 
 
FCS 
 100 mM Hepes (only to RPMI 1640) 
 2 mM  L-Glutamin 
 1 mM Sodium Pyruvate 
 100 U Penicillin 
 100 µg Streptomycin 
 1x MEM non essential amino acids 
2.4 Viruses 
Tab. 2: Viruses 
VZV strain 
 
Genotype Source 
 
V-Oka 
 
J 
 
Attenuated vaccine (V-) strain Oka “Varilrix” from  
GlaxoSmithKline (Rixensart, Belgium) 
 
P-Oka J Parental (P)-Oka strain of VZV
3
 
 
JoSt E1 Clinical isolate of varicella patient, Germany 
 
M1_935/05 M1 Clinical isolate of varicella patient, Germany 
 
E2_769/05 E2 Clinical isolate of varicella patient, Germany 
 
E1_667/05 E1 Clinical isolate of varicella patient, Germany 
   
 
3
 The P-Oka strain of VZV was kindly provided by K. Tischer, Freie Universität Berlin, Institute of 
Virology, Berlin, Germany 
 All VZV strains were genotyped by Prof. Sauerbrei at the Institute of Virology and Antivir-
al Therapy of the Friedrich Schiller University of Jena (Germany) as previously published
169
. 
Partial sequencing revealed that the P-Oka strain harbored several mutations within ORF1 and 
ORF21 compared to the reference P-Oka strain. This is in line with the reports of K. Tischer that 
the isolate was already highly passaged in cell culture. Therefore, further investigations did not 
include the P-Oka strain of VZV. 
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 VZV was propagated in confluent HELF monolayers (maximum after two days post seed-
ing) consisting of VZV-infected and uninfected cells (ratio of 1:7). As inoculums VZV-infected 
trypsin-dispersed cells were used
170
. Two days post inoculation cytopathic effect (CPE) typically 
reached 80-100 %. VZV stocks (VZV-infected cells) were frozen in media with 10% DMSO (Roth, 
Germany) and stored in liquid nitrogen. The titer of VZV stocks were determined by calculation 
of the TCID50 by the Reed-Muench formula on HELF cells and tested for mycoplasma contami-
nations using Venor GEM-Mykoplasmen Detektion Kit from Minerva biolabs (Berlin, Germany) 
according to the manufacturer`s instructions. 
The HSV-1 strain KOS was propagated in Vero E6 cells and kindly provided by M.J. Raftery.  
2.5 Antibodies 
 
The following mouse monoclonal antibodies were used for following analysis: fluorescence 
activated cell sorter (FACS), immunofluorescence (IF), western blot (WB) or enzyme linked im-
munosorbant assay (ELISA). 
Tab. 3: Primary Antibodies 
Specificity 
 
Clone Application Company 
Actin (beta) AC-15 WB Abcam (Hiddenhausen, Germany) 
CD107a H4A3 FACS BD Biosciences (Heidelberg, Germany) 
CD154-PE (CD40L) TRAP1 FACS BD Biosciences (Heidelberg, Germany) 
CD1a HI 149 FACS, IF ImmunoTools (Friesoythe, Germany)  
CD1b 4.A7.6 FACS, IF IMMUNOTECH (Marseille, France) 
CD1c L161 FACS, IF IMMUNOTECH (Marseille, France) 
CD206 19.2 FACS, IF BD Biosciences (München, Germany) 
CD209  FACS, IF Acris Antibodies  (Herford, Germany) 
CD3 UCHT1 FACS, IF BD Biosciences (Heidelberg, Germany) 
CD40 5C3 FACS, IF BD Biosciences (Heidelberg, Germany) 
CD40-PE 5C3 FACS BD Biosciences (Heidelberg, Germany) 
CD83 HB15e FACS, IF BD Biosciences (Heidelberg, Germany) 
CD83-FITC HB15e FACS BD Biosciences (Heidelberg, Germany) 
CD86 IT2.2 FACS, IF BD Biosciences (Heidelberg, Germany) 
CD86-PE-Cy5 2331 (FUN-1) FACS BD Biosciences (Heidelberg, Germany) 
gE MAB8612 FACS, IF, WB MILLIPORE (Schwalbach, Germany) 
IgG1 MOPC-21 FACS, IF BD Biosciences (Heidelberg, Germany) 
IgG2b MPC-11 FACS, IF BD Biosciences (Heidelberg, Germany) 
p38  
MAP Kinase 
9212 WB Cell Signaling Technology  
(Danvers, USA) 
p44/42  
MAP Kinase 
9102 WB Cell Signaling Technology  
(Danvers, USA) 
Phospho-p38  
MAP Kinase 
(Thr180/Tyr182) 
9211 WB Cell Signaling Technology  
(Danvers, USA) 
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Phospho-p44/42 
MAP Kinase 
(Thr202/Tyr204) 
9101 WB Cell Signaling Technology  
(Danvers, USA) 
Phospho-SAPK/JNK 
(Thr183/Tyr185) 
9251 WB Cell Signaling Technology  
(Danvers, USA) 
SAPK/JNK 9252 WB Cell Signaling Technology  
(Danvers, USA) 
γδ TCR 11F2 FACS, IF MILLIPORE (Schwalbach, Germany) 
 
 
Tab. 4: Secondary Antibodies 
Specificity 
 
      Application       Company 
Alexa_488_IgG2b IF Invitrogen (Karlsruhe, Germany) 
Alexa_568_IgG1 IF Invitrogen (Karlsruhe, Germany) 
Allophycocyanin-conjugated 
AffiniPure IgG, Fcγ subclass 
2b specific 
FACS Dianova (Hamburg, Germany) 
Cy5-conjugated AffiniPure 
IgG 
FACS Dianova (Hamburg, Germany) 
FITC-conjugated AffiniPure 
IgG  
FACS Dianova (Hamburg, Germany) 
Peroxidase conjugated 
Streptavidin 
ELISA Dianova (Hamburg, Germany) 
Peroxidase-conjugated  
AffiniPure F(ab`)2 Fragment 
WB, ELISA Dianova (Hamburg, Germany) 
R-Phycoerythrin-conjugated 
AffiniPure IgG 
FACS Dianova (Hamburg, Germany) 
R-Phycoerythrin-conjugated 
AffiniPure IgG Fcγ subclass 1 
specific 
FACS Dianova (Hamburg, Germany) 
 
2.6 Fluorescent Dyes 
 
Tab. 5: Fluorescent Dyes 
Specificity 
 
      Application       Company 
AnnexinV (sc-4252) FACS Santa Cruz Biotechnology  
(Heidelberg, Germany) 
DAPI IF Invitrogen (Karlsruhe, Germany) 
Propidium iodide (sc-3541) FACS Santa Cruz Biotechnology  
(Heidelberg, Germany) 
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2.7 Chemicals 
 
Tab. 6: Chemicals 
Name 
 
Company 
APS Roth (Karslruhe, Germany) 
Collagenase  CellSystem (St. Katharinen, Germany) 
Coomassie blue Serva (Heidelberg, Germany) 
Dispase I Puritiy grade I; Roche (Mannheim, Germany) 
DMSO Roth (Karslruhe, Germany) 
DNase Roche (Mannheim, Germany) 
EDTA AppliChem (Darmstadt, Germany) 
Eosin Y solution Merck (Darmstadt, Germany 
Ethanol Roth (Karslruhe, Germany) 
FCS Hyclone, Perbio Sciences (Bonn, Germany) 
Formaldehyd Merck (Darmstadt, Germany) 
Hyaluronidase type I S  Sigma Aldrich (München, Germany) 
Isopentane Roth (Karlsruhe, Germany) 
Isopropanol Roth (Karslruhe, Germany) 
LPS Sigma-Aldrich (Hamburg, Germany) 
LTA InvivoGene (San Diego, USA) 
Mercaptoethanol Merck (Darmstadt, Germany) 
Methanol Roth (Karslruhe, Germany) 
Molecular weight marker  Fermentas (St. Leon-Rot,Germany) 
Monensin  Sigma-Aldrich(Hamburg, Germany) 
Papanicolau`s solution Merck (Darmstadt, Germany) 
PHA-L Sigma-Aldrich (Hamburg, Germany) 
Recombinant hu GM-CSF ImmunoTools (Friesoythe, Germany) 
Recombinant hu IL-4 ImmunoTools (Friesoythe, Germany) 
Rotiphorese-Acrylamid Roth (Karslruhe, Germany) 
SDS Merck (Darmstadt, Germany) 
Stop-Solution Medac (Hamburg,Germany) 
Sucofin skim milk powder TSI (Zeven, Germany) 
TEMED Roth (Karslruhe, Germany) 
TMB-Substrate Medac (Hamburg,Germany) 
Tris-Aminomethan Roth (Karslruhe, Germany) 
Tris-HCl Roth (Karslruhe, Germany) 
Trypsin/EDTA Invitrogen (Karlsruhe, Germany) 
Tween-20 Roth (Karslruhe, Germany) 
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2.8 Buffers and Solutions 
 
Tab. 7: Buffers and Solutions 
Name 
 
Ingredients Name Ingredients 
Apoptosis buffer 10 mM Hepes, pH 7.4 
0.14 M NaCl 
5 mM CaCl2 
5% FCS 
0.02% sodium azide 
FACS block PBS Solution 
10% FCS 
0.02% sodium azide 
Coomassie  
 
Destain solution with 
2.5% coomassie-blue 
FACS wash 
 
PBS Solution  
1% FCS 
0.02% sodium azide 
Destain  7% acetic acid 
10% methanol 
Ad dd H20 
Fixation  PBS Solution 
0.37% formaldehyde 
Electrophoresis buf-
fer 
0.06 M Tris-
aminomethan 
0.2 M Glycin 
0.1% SDS 
PBS  2 mM NaH2PO4 
6.5 mM Na2HPO4 
150 mM NaCl 
ELISA coating buffer 100 mM Carbo-
nat/bicarbonate buf-
fer,  
pH 9.6 
Resolving gel  0.9 M Tris-
aminomethan 
0.4% SDS 
pH 8.8 
ELISA blocking buffer PBS with 5% skimmed 
milk 
Stacking gel 0.3 M Tris-
aminomethan 
0.4% SDS 
pH 6.8 
ELISA wash buffer PBS with 0.05% 
Tween-20 
Transfer buffer 0.8 M Tris-
aminomethan 
0.4 M Glycin 
20% Methanol 
pH 8.0  
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2.9 Kits 
 
Tab. 8: Kits 
Name 
 
Company 
BCA Protein Assay Kit Pierce (Rockford, USA) 
CD1c (BDCA-1)
+
Dendritic Cell Isolation Kit, hu Miltenyi Biotech (Bergisch-Gladbach, Germany) 
Complete Protease Inhibitor Cocktail Tablets, Roche (Mannheim, Germany) 
IFN-γ ELISA ImmunoTools (Friesoythe, Germany) 
IL-12p70 ELISA Ready-SET-Go, eBioscience  
(EW Breda,Netherland) 
MACS columns  Large cell, LD and MS, Miltenyi Biotech (Berg-
isch-Gladbach, Germany) 
Monocyte Isolation Kit II Miltenyi Biotech (Bergisch-Gladbach, Germany) 
mRNA Isolation  MagNA Pure LC mRNA Isolation Kit-I Lysis 
Buffer Refill, Roche (Mannheim, Germany) 
Mycoplasma Detection Venor GEM-Mykoplasmen Detektion Kit, Mi-
nerva biolabs (Berlin, Germany) 
 
2.10 Equipment 
 
Tab. 9: Equipment 
Name 
 
Type and Company 
Anti-roll plate, glass 50 mm, Leica Microsystems GmbH (Nussloch, Germany) 
Kodak Image Station  4000 MM, Kodak (Stuttgart, Germany)  
Cell counting chamber 
Cell counting 
Neubauer improved, Roth (Karlsruhe, Germany) 
CASY I, Schaerfe System (Reutlingen, Germany) 
Centrifuges Megafuge 2.O R, Heraeus (Hanau, Germany) 
CO2 Incubator HERACell 150, Heraeus (Hanau, Germany) 
Cryomolds Tissue-Tek 4565, Sakura (Zoeterwoude, Netherlands) 
Cryostat Jung, Frigocut 2800N, Leica Microsystems Nussloch (Nuss-
loch, Germany)  
Electronic pipetor Pipetus, Hirschmann Laborgeräte (Eberstadt, Germany) 
Electrophoresis System BIO-RAD Laboratories (München, Germany) 
Flow Cytometer FACSCalibur and FACSCanto II, BD Biosciences (Heidelberg, 
Germany) 
Fluorescence Microscope Olympus BX60, Carl Zeiss (Jena, Germany) 
Freezing spray Solidofix, Roth (Karlsruhe,Germany) 
Microscope Axiovert 25, Carl Zeiss (Jena, Germany) 
Microscope slides SuperFrost Ultra Plus, Menzel (Braunschweig, Germany)  
Sterile filters 0,2 µm, Schleicher and Schüll (Dassel, Germany) 
300 µm and 40 µm Nylon, BD Biosciences (Heidelberg, Ger-
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many) 
Sterile Workbench HERASafe, Heraeus (Berlin, Germany) 
Tissue Freezing Medium Jung, Leica Microsystems (Nussloch, Germany) 
Vortex Vortex-Genie 2, Scientific Industries (New York, USA) 
Waterbath GFL (Burgwedel, Germany) 
Whatman Paper Schleicher and Schüll (Dassel, Germany) 
 
2.11 Quantitative RT-PCR  
Quantitative reverse transcriptase PCR (qRT-PCR) for CD1, CD40 and CD86 genes  was per-
formed using 5 x 10
5
 iDCs collected in 300 µl lysis buffer from the MagnaPure mRNA isolation 
kit I (Roche Diagnostics, Mannheim, Germany).  Messenger RNA (mRNA) was isolated with the 
MagnaPure-LC device by using the mRNA kit I standard protocol. The elution volume was set to 
50 µl. An aliquot of 8.2 µl of RNA was reverse transcribed by using avian myeloblastosis virus RT 
and oligo dT. After the termination of the cDNA synthesis, the reaction mix was diluted to a 
final volume of 500 µl and stored at –20°C until PCR analysis. Primer sets specific for CD1a to 
CD1c, CD40 and CD86 genes and optimized for the LightCycler were developed and provided by 
SEARCH-LC. PCR was performed with the LightCycler FastStart DNA Sybr green kit I (Roche Di-
agnostics, Mannheim, Germany) according to the manufacturer`s instructions. The calculated 
copy numbers were normalized according to the average expression of two housekeeping 
genes, the cyclophilin B and beta-actin. All qRT-PCR`s were analyzed by T. Giese at the Universi-
ty of Heidelberg, Institute of Immunology (Heidelberg, Germany).  
 
2.12 Immunological Methods 
 
2.12.1 Isolation of Monocytes from Buffy Coats  
Buffy coat preparations (∼ 60 ml) were supplied by the Deutsche Rote Kreuz (Dresden, Germa-
ny) and diluted 1:1 with media containing 0.2 mM EDTA. The diluted blood was carefully 
layered on top of 20 ml of Ficoll-Hypaque in a 50 ml falcon tube (LSM1077, PAA Laboratories 
GmbH, Marburg, Germany). To separate the blood cells, tubes were centrifuged for 20min at 
room temperature at 800 g without brake. Thereafter, the white ring containing PBMCs was 
collected and washed with medium. To eliminate thrombocytes, the cells were once centri-
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fuged at 200 g for 5min and the supernatant was carefully removed. The PBMCs were resus-
pended in 10 ml media and carefully layered on top of diluted Ficoll-Hypaque (1.4 ml PBS was 
added to 10 ml Ficoll-Hypaque). The tubes were centrifuged again at 800 g for 25min at room 
temperature and the white PBMC ring was harvested. For isolation of untouched monocytes, 
the Monocyte Isolation Kit II was used according to the manufacturer`s instruction.  The cells 
were washed once in cold MACS buffer and then incubated for 10min at 4°C with 200 µl of 
human FcR blocking reagent and 200 µl of monocyte Biotin-Antibody Cocktail containing 
mouse monoclonal antibodies anti human CD3, CD7, CD16, CD19, CD56, and Gylcophorin A to 
label non-monoyctes (T cells, B cells, NK cells, DCs and basophiles). Thereafter, 1 ml ice-cold 
MACS buffer and 400 µl Anti-Biotin MicroBeads were added to. After another incubation time 
of 15min at 4°C the labeled cells were adjusted to an equilibrated LS column. The untouched 
monocytes were collected from the flow through and washed twice in media. To differentiate 
monocytes into immature DCs, GM-CSF (500 IU/ml) and IL-4 (200 IU/ml) were added to the 
culture medium. Entire medium was replaced on day three post isolation when DCs were used 
for viral infection. Immature DCs were analyzed for cell surface expression of CD1a, CD1c and 
DC-SIGN. 
 
2.12.2 VZV Infection of Immature DCs 
After 3d of differentiation, 1 to 2 x 10
6 
immature DCs were centrifuged at 150 g for 45min at 
room temperature onto VZV-infected HELF monolayer (24-well plate). VZV-infected HELF mo-
nolayers showed cytopathic effects of 75-90% with a TCID50 of ∼ 2,7x 10
4
 PFU/ml. Mock-
infected cultures were set up as described above using uninfected HELFs. DCs were removed 
24h post transmission and placed into a new T75 culture flask. After 2d post VZV transmission 
flow cytometry analysis and T cell assays were performed (Fig.7).  
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Fig. 7: Experimental setting for phenotypic and functional analysis of VZV-infected DCs.  
Monocytes were isolated from buffy coats derived from healthy individuals and differentiated within 
three days into immature mo-DCs (iDCs). Human embryonic lung fibroblasts (HELF) were infected with 
VZV and 2d post VZV infection iDCs were centrifuged on VZV-infected monolayers showing cytopathic 
effects (CPE) of about ∼80%. After 24h of coculture iDCs were gently removed from the VZV monolayer 
and cultured for another 24h. Two days post infection VZV-infected iDCs were analyzed by flow cytome-
try for surface expression and used for stimulation of CD1c-restricted γδT cells.  
2.12.3 Flow Cytometry  
To detect cell surface expression by flow cytometry cells were washed once with ice-cold FACS 
wash solution before being resuspended with the primary antibodies in ice-cold blocking solu-
tion for 1h. Cells were then washed with FACS wash solution and stained for 45min with sec-
ondary fluorophore-conjugated antibodies. After another washing step cells were fixed with 
0.37% formaldehyde and analyzed by flow cytometry with a FACSCalibur or FACSCanto II. Data 
were analyzed wit Cellquest Pro software.  
2.12.4 Detection of Apoptotic Death 
A characteristic early event during apoptosis is the loss in membrane asymmetry which results 
in the translocation of phosphatidylserine from the inner to the outer leaflet of the plasma 
membrane. Once exposed to the extracellular environment, phosphatidylserine can be de-
tected through AnnexinV, a Ca
2+
 -dependent phospholipid binding protein. Due to the loss in 
membrane integrity in the process of cell death nucleic acids become accessible for the inter-
calating dye propidium iodide (PI). Staining for AnnexinV indicates early events of apoptosis 
whereas additional staining for propoidium iodide is characteristic for later stages of apoptosis 
or necrosis.  
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During the whole staining procedure the cells must be kept in the apoptosis buffer con-
taining 5 mM calcium. Apoptotic death was investigated using AnnexinV conjugated to the 
fluorophore FITC and propidium iodide. 
Cells were harvested and washed once with apoptosis buffer. AnnexinV was added to 
the cells and incubation was performed at 4°C for 20min. After another washing step cells 
were kept on ice and immediately analyzed by flow cytometry. The sample was firstly analyzed 
for AnnexinV positive cells and thereafter propidium iodide was added to the sample. After an 
incubation time of 2-3min at 4°C the samples were measured for double-positive cells.  
2.12.5 T Cell Assays 
All T cell assays were performed with the well characterized CD1c-restricted γδ T cell clone 
JR.2.28
131
. The T cell clone was cultured by periodic stimulation with PHA in the presence of 
irradiated EBV-transformed B cells and PBMCs as described
131
. 
2.12.5.1 Cytokine Secretion Assay  
5 x 10
5
 T cells were cocultured with 5 x 10
5
 mock or VZV-infected iDCs in a flat bottom 96-well 
plate. As positive control, T cells were stimulated with PHA. Supernatants were harvested after 
48h of coculture and stored at –20°C. Cytokine release was determined for IFN-γ and bioactive 
IL-12p70 by ELISA. 
2.12.5.2  Cytotoxicity Assay  
To verify cytotoxic activity of γδ T cells cell surface expression of CD107a (Lamp-1) was detected 
as previously described
171,172
. The effector-target ratio (E-T ratio) was 1:1. Therefore, 2 x 10
5
 γδ 
T cells were co-cultured with 2 x 10
5 
mock or VZV-infected DCs in a flat bottom 96-well with a 
final volume of 200 µl. The CD107a antibody (15 µl) was directly added to the cells within the 
first hour of incubation at 37°C and 5% CO2. Thereafter, 5 µl of the secretion inhibitor monensin 
(2 mM) was added to the wells. After a further incubation period of 4h at 37°C and 5% CO2 cells 
were washed once with PBS and then stained with antibodies for flow cytometry analysis. To 
detect spontaneous degranulation of the T cells a control sample without target cells was in-
cluded in every experiment.  
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2.12.6 ELISA 
To detect and quantify the cytokine concentration in unknown samples we used the two-
antibody sandwich Enzyme Linked Immunosorbant Assay (ELISA). The ELISAs were performed 
according to the instructions of the manufacturer. Briefly, the capture antibody for the corres-
ponding cytokine was bound overnight at 4°C by softly shaking to the 96-well flat bottom plate. 
After washing the plate, wells were blocked with blocking buffer for 1h at RT. Then, the plate 
was washed several times with washing buffer. Thereafter, the corresponding standard cytokine 
in appropriate dilutions and the unknown samples were applied to each well and incubated for 
2h at RT (carefully shaking). After several washing steps the biotinylated detection antibody 
was added and allowed to bind to the cytokine during incubation time of 1h at RT under softly 
shaking. The enzyme horseradish peroxidase (HRP) coupled to streptavidine was added for 
30min after several washing steps. Then, the substrate 3, 3`, 5, 5` -tetramethylbenzidine (TMB) 
was added for a maximum of 30min. After incubation in the dark the reaction was stopped by 
adding 2N H2SO4 to each well. The color density was measured at 450 nm. The cytokine con-
centration in unknown samples was calculated according to the standard curve of the standard 
antigen.  
2.12.7 Immunhistochemistry 
Skin sections were stained for 30s with Papanicolaus solution (dilution 1:2 with H20) and finally 
washed several times with tap water. Afterwards, slides were stained with Eosin solution for 2 
min. After excessive washing slides were finally mounted with mounting media (Kaiser`s Glyce-
ringelatine with Pheno) from Merck (Darmstadt, Germany) for histology.  
Skin sections from biopsies were washed once with PBS to remove acetone and then 
blocked for 1h at room temperature with 5% goat serum in FACS block solution. Incubation of 
primary antibodies was performed in a humified chamber at 37°C for 1h. Slides were washed 
with PBS before incubation of secondary antibodies at room temperature for 45min. In this 
step staining of nuclear DNA with DAPI (1/20 000) was also performed. Slides were finally cov-
ered with mounting medium from Dako (Hamburg, Germany). The stained skin sections were 
analyzed by fluorescence microscopy. 
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2.12.8 Immunoblot Analysis 
Mock or VZV-infected iDCs (2d p.i.) were stimulated for 15min with control or CD40L-
expressing adherent cells. DCs were then lysed in lysis buffer containing 0.1% NP40, 80 mM KCl, 
50 mM Tris-HCl, pH 7.5, 10 mM EDTA and a protease inhibitor cocktail. Cell lysates were sepa-
rated by SDS-PAGE and transferred to polyvenylidene difluoride (PVDF) membranes. Mem-
branes were stained with the appropriate specific antibodies and visualized with an enhanced 
chemiluminescence system from Perbio Science (Bonn, Germany). 
2.13 Statistics 
The program SPSS 14.0 was used to perform statistics. The Wilcoxon test was used to deter-
mine the significance of differences between groups. P values of less than 0.05 were consi-
dered significant (two-tailed). The actual P values are indicated in the Box-Whisker-Plots. Boxes 
cover the middle 50% of the data values between the 25
th
 and 75
th
 percentiles, the central line 
being the median. Endpoint of whiskers represents true data points for smallest and biggest 
values.     
2.14 Software  
 
Tab. 10: Software 
Name 
 
Company 
Adobe Photoshop CS3 (München, Germany) 
CellQuest Pro BD Biosciences (Heidelberg, Germany) 
CorelDraw X3 (Unterschleißheim, Germany) 
SPSS 14.0 (Chicago, USA) 
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3 Results 
 
3.1 Propagation of VZV Strains in Fibroblasts 
VZV is highly cell-associated in vitro and therefore propagation of the virus must be per-
formed by coculture of VZV-infected cells with uninfected cells. VZV replication can be rea-
dily observed due to its typical plaque formation within the confluent monolayer (Fig.8). 
The VZV-induced cytopathic effect (CPE) in fibroblasts is characterized by syncytia forma-
tion and ballooning of the cells
173
.  
 
Fig. 8: Cytopathic effect (CPE) of VZV in fibroblasts.  
Phase contrast microscopy images of mock-infected human embryonic lung fibroblasts (HELF) and VZV-
infected HELF after 2d p.i. (20x magnification).   
Initially, growth kinetics of attenuated vaccine strain V-Oka and clinical isolate JoSt 
were assessed in human embryonic lung fibroblasts (HELF). No differences in the replica-
tion capacity could be observed for both viral strains (Fig. 9a). To ensure identical titer dur-
ing the transmission of VZV to iDCs the titer of a 24-well of VZV-infected HELF cells 2d p.i. 
was determined for each independent experiment (Fig. 9b). The titers were for the vaccine 
3.12 x 10
4
 PFU/ml (mean) and for the JoSt strain 3.29 x 10
4
 PFU/ml (mean) thereby nearly 
identical (n=12).   
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Fig. 9: No differences in viral replication of the vaccine strain Oka (V-Oka) and a clinical isolate JoSt in 
cell culture.  
(a) Growth kinetic of V-Oka and JoSt infected HELFs. The titer was determined as plaque forming unit 
(PFU) per 24-well. Cells were infected with an inoculum of 300 PFU of cell-associated virus (VZV-infected 
cells) and harvested every day until four days post infection (4d p.i.). Results shown as mean ± 1 SD, were 
derived from three independent experiments done in duplicates for each virus. (b) The titer of VZV-
infected fibroblasts (2d p.i.) within a 24-well was determined to validate equal infection of iDCs (n=12). 
A main focus of this study was to compare the immunological response to vaccine 
strain V-Oka with that induced by clinical isolates circulating in Germany. All viral strains 
used were partly sequenced and genotyped (Fig. 10). 
 
Fig. 10: Phylogenetic tree of VZV strains.  
All VZV strains used belong to one of the following genotypes: J, M1, E2 and E1. VZV reference strains (in 
italics) were integrated within the phylogenetic tree. The investigated VZV strains in this study cluster in 
the following genotypes: the vaccine strain V-Oka clustered within genotype J, M1_935/05 belongs to 
genotype M1, E2_769/05 is representative for genotype E2 and E1_667/05 and JoSt belongs to the geno-
type E1. The length of the indicated marker represents 0.1 nucleotide exchange.  
The efficiency of infection of the different genoytpes of VZV was assessed by immu-
nofluorescence microscopy analysis in HELF cells (Fig. 11). VZV infection of HELF cells in-
duced typical syncytia formation as revealed by DAPI staining. The infection was visualized 
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with a VZV patient serum. No differences in the infection efficiency could be observed for 
the clinical isolates of VZV.  
 
Fig. 11: Growth of VZV clinical isolates in fibroblasts.  
HELFs grown on coverslides were infected with VZV clinical isolates as indicated. After 2d cells were fixed 
with methanol/acetone (1:1) and stained for VZV infection with a VZV patient serum (1/100). Cellular 
nuclei were visualized with DAPI (1/20 000). In VZV-infected cells the characteristic formation of syncytia 
could be observed. (10x magnification).     
 
3.2 Distribution of DCs within Skin Lesions of Herpes Zoster Patients 
The skin comprises distinct compartments harboring different types of DCs that function as 
sentinels for invading pathogens. Langerhans cells (LC) of the epidermis express on their 
cell surface CD1a and Langerin which capture antigen from the surrounding environment. 
Dermal dendritic cells (DDC) are located in the dermis and express CD1b, CD1c and DC-
SIGN (DC-specific intercellular adhesion molecule-3-grabbing non-integrin) on the cell sur-
face. To investigate which type of DC is involved during VZV pathogenesis we analyzed skin 
sections from punch biopsies of immunocompetent herpes zoster patients.  
Frozen skin sections of healthy control and herpes zoster patients were initially 
stained with Papanicolaou`s solution and eosin to visualize differences in tissue morpholo-
gy (Fig.12). Compared to control skin herpes zoster lesions were characterized by extensive 
formation of multi-nucleated polykaryocytes, a gradual thickening of the epidermis, epi-
dermal cell proliferation and cellular degeneration (Fig. 12b). In the vesicles, acantholysis 
(loss of intercellular connections between keratinocytes), destruction of the epidermis as 
well as the upper part of the dermis was observed. Additionally, local massive infiltration of 
inflammatory cells was detected.  
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Fig. 12: Tissue biopsies of healthy control individuals and herpes zoster patients.  
Frozen skin sections (5µm) were stained with Papanicolaou`s solution and eosin to visualize morphologi-
cal changes within the tissue. The epidermis is orientated upwards. (a) Skin section of healthy control. (b) 
Skin section of herpes zoster patient (10x magnification). Sections of one representative biopsy of two 
are shown. 
To characterize the massive infiltration of inflammatory cells in herpes zoster lesions 
skin sections were assessed by immunofluorescence microscopy (Fig. 13). Staining of nuclei 
with the DNA-intercalating dye DAPI showed the structured organisation of the control 
skin. In contrast, VZV-infected tissue of herpes zoster (HZ) patients showed the typical 
thickening of the epidermis and locally a strong infiltration of inflammatory cells within the 
dermis. VZV infection was visualized by detecting the late viral gene product glycoprotein E 
(gE) which is the most abundantly expressed glycoprotein during VZV infection. In the 
herpes zoster sections staining for gE localized the VZV containing vesicle within the epi-
dermis and dermis. As expected, no signal could be detected in the control skin. Staining 
for the integrin CD11c, a marker which is exclusively expressed on myeloid cells, detected 
the infiltration of myeloid cells within the VZV-infected tissue. CD1a and Langerin express-
ing LCs were evenly distributed in the epidermis of the control skin but absent in the 
herpes zoster skin. CD1b and CD1c expressing DDCs were evenly distributed in the upper 
dermis of the control skin. In strong contrast, CD1b expressing DDCs were found to strongly 
infiltrate herpes zoster lesions. Few CD1c expressing DDCs could be detected in close 
neighbourhood of the VZV vesicle.  
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Fig. 13: Dual immunofluorescence microscopy analysis of skin sections from control and herpes zoster 
(HZ) biopsies.  
Nucleic acids were stained with the DNA intercalating dye DAPI (1/20 000). All sections are orientated 
with the epidermis upwards. Sections were stained for viral glycoprotein E (gE), Langerhans cell markers 
Langerin and CD1a, CD11c as a marker of myeloid DCs, the molecules CD1b, CD1c and DC-SIGN ex-
pressed on dermal dendritic cells (DDCs), CD206 as macrophage marker and CD3 to detect T cells. One 
representative skin section of two biopsies is shown. White scale bar represents 200 µm.  
Intriguingly, CD1c expressing DDCs were detected in close contact to the VZV vesicle but 
remained undetectable in the surrounding dermis. Furthermore, staining for the marker 
DC-SIGN and CD206 (mannose-6 phosphate receptor) showed that the infiltrated cells 
within the dermis of the herpes zoster patient comprise DDCs and macrophages.  
Staining for CD3 showed that the infiltrated cells within the herpes zoster biopsy also con-
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tained T cells. Staining for tissue-specific Vδ1 γδ T cells was not possible which might be 
due to lack of sensitivity of the antibody used or due to emigration of γδ T cells to the local 
lymph node. Altogether these data provide evidence that myeloid DCs expressing CD1 mo-
lecules play a role in the cutaneous immune response against VZV.  
Blood samples from herpes zoster patients in the acute phase of infection were ana-
lyzed to determine the percentage of circulating γδ T cells. Recently, a role for these cells in 
patients resolving cytomegalovirus infection was found
166
. Peripheral blood mononuclear 
cells (PBMCs) were stained for the expression of CD3 and γδ TCR and analyzed by flow cy-
tometry (Fig. 14a). Slightly reduced percentages of peripheral γδ T cells were observed in 
herpes zoster patients compared to healthy control persons (Fig. 14b). The observed varia-
tion between 1% and 10% of γδ T cells within the control group is a common observed 
finding and can be explained by the donor variability.    
 
Fig. 14: Percentage of γδ T cells in peripheral blood from healthy control and herpes zoster (HZ) pa-
tients as determined by flow cytometry.  
(a) Histograms showing γδ TCR expression on CD3
+
 T cells. One representative experiment is shown. (b) 
Percentage of CD3
+
/γδ TCR
+
 cells in peripheral blood mononuclear cells from healthy control (co, n=17) 
and herpes zoster (HZ) patients (acute phase of infection; n=4) is shown. Opened triangles and circles 
represent data points of patients. The median is indicated as black bar.  
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3.3 VZV Infection of Cutaneous DCs 
In order to assess the question if cutaneous DCs are permissive to VZV infection, LCs and 
DDCs were isolated by magnetic bead technique from human skin. Staining for myeloid 
marker CD11c and Langerin on LCs (Fig. 15a) and CD11c and CD1c on DDCs (Fig. 15b) con-
firmed the purity of the preparations.  
 
Fig. 15: Isolation of cutaneous DCs from human skin.  
(a) LCs were isolated from epidermis and analyzed by flow cytometry for expression of CD11c and Lang-
erin or respective isotype controls. (b) DDCs were isolated from dermis and purity was confirmed by 
staining for CD11c and CD1c. One representative experiment of two is shown.   
Freshly isolated LCs and DDCs were used to investigate the permissivity to VZV infec-
tion. Due to the highly cell-associated nature of VZV in vitro LC and DDC infection was per-
formed by coculture with VZV-infected fibroblasts. To detect and quantify the infection rate 
of VZV, 2d p.i. LCs and DDCs were stained for the cell surface expression of glycoprotein E 
(gE) (Fig. 16). Mock LCs and DDCs did not express gE on the cell surface, whereas on VZV-
infected LCs and DDCs expression of gE was detected. Importantly, no differences in the 
efficiency of infection could be observed between the vaccine strain V-Oka and the clinical 
isolate JoSt.  
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Fig. 16: Cutaneous DCs are permissive to VZV infection.  
LCs and DDCs were cocultured with mock, V-Oka or JoSt infected iDCs and analyzed by flow cytometry 2d 
p.i. for cell surface expression of viral glycoprotein E (gE). Percentage of gE positive cells are indicated in 
the histograms. One representative experiment of two is shown. 
 
3.4 Phenotype of VZV Infected Cutaneous DCs 
Cutaneous migratory DCs are part of the immune surveillance system in the body`s largest 
and most exposed interface with the environment, the skin. LCs and DDCs play a central 
role in host defence and are therefore well equipped to sense early invading pathogens 
through PRRs. After uptake of foreign antigens they undergo phenotypic and functional 
maturation which are characterized by expression of a set of maturation molecules like 
CD83, CD86 and CD40 among many others. The skin represents the major replication site 
of VZV. Therefore, phenotypic changes were analyzed by flow cytometry on VZV-infected 
LCs and DDCs (Fig. 17).  
Contact of LCs with fibroblasts induced maturation in a small LC-population as cell 
surface expression of CD83 and CD86 on mock-infected LCs show. Furthermore, CD40 was 
expressed in high amounts on mock LCs. VZV infection of LCs did not induce upregulation 
of CD83 and CD86 on LCs. Additionally, cell surface expression of CD40 was decreased 
compared to mock infected LCs. 
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Fig. 17: VZV does not induce phenotypic maturation on LCs.  
Mock and VZV-infected LCs were analyzed for cell surface expression of CD83, CD86 and CD40 by flow 
cytometry. Percentage of positive cells for CD83 and CD86 expression and MFI for CD40 expression are 
indicated in the histograms. One representative experiment of two is shown. 
Contact of DDCs with fibroblasts or VZV infection did not induce phenotypic matura-
tion of DDCs as cell surface staining for CD83 and CD86 demonstrated (Fig. 18). Interest-
ingly, a decrease in CD40 cell surface expression on VZV-infected DDCs compared to mock 
infected DDCs was observed.    
 
Fig. 18:  VZV infection of DDCs does not induce phenotypic maturation.  
Mock and VZV-infected DDCs were stained for cell surface expression of CD83, CD86 and CD40 and ana-
lyzed by flow cytometry. Percentage of positive cells for CD83 and CD86 expression and MFI for CD40 
expression are indicated in the histograms. One representative experiment of two is shown. 
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Alltogether, these data provide evidence that VZV infection of cutaneous DCs did not 
induce phenotypic maturation and thereby prevents innate antiviral immune responses. 
Furthermore, VZV decreases CD40 expression on LCs and DDCs an important co-
stimulatory molecule for the reciprocal crosstalk of DCs and T cells.   
 
3.5 Transmission of VZV to Immature DCs 
Demonstrating that cutaneous DCs are permissive to VZV infection and phenotypically 
modulated by VZV, further investigations were performed with monocyte-derived iDCs for 
several reasons. A key point is that iDCs can be differentiated from monocytes in high 
amounts compared to limited numbers of LCs and DDCs obtained from human skin. This is 
of importance because experiments with VZV are very cell consuming due to the highly 
cell-associated nature of VZV. Furthermore, iDCs reflect best inflammatory DCs which have 
been shown to differentiate from recruited monocytes into “dermal monoctye-derived 
DCs” during Leishmania infection
96
. Moreover, infiltration of myeloid DCs was observed in 
skin biopsies of herpes zoster patients and it was shown by Abendroth et al. that iDCs are 
productively infected by VZV and transmit the virus to T cells permitting viral spread
20
.  
Before investigation of phenotype and function of VZV-infected iDCs the efficiency of 
infection of iDCs with the vaccine strain V-Oka and the virulent clinical isolate JoSt were 
analyzed. Interestingly, the morphology of iDCs changed after transmission of VZV. Com-
pared to the single-cell morphology in the mock control, VZV-infected iDCs formed clusters 
(Fig. 19).  
 
Fig. 19: Morphology of iDCs 2d p.i. with VZV.  
Phase contrast microscopy images of mock, V-Oka and JoSt infected iDCs (10x magnification).  
53 
VZV infection by the vaccine strain V-Oka or clinical isolate JoSt was verified 2d p.i. by 
staining for cell surface expression of gE on iDCs (Fig. 20). Mock iDCs did not express gE on 
the cell surface, whereas on VZV-infected iDCs the expression of gE was detected (Fig. 20a). 
Interestingly, within the VZV-infected iDCs two populations (M1 and M2) were observed. 
The main population of VZV-infected iDCs (∼75%) expressed gE in only low numbers on the 
cell surface (M1), whereas a minor population of less than 20% expressed high numbers of 
gE on the cell surface (M2, Fig. 20b). This phenomenon was observed for both VZV strains.  
 
Fig. 20: Efficiency of VZV infection of iDCs.  
(a) Flow cytometry analysis of iDCs 2d p.i. with VZV. Histograms show surface expression of viral glyco-
protein E (gE) on mock, V-Oka and JoSt infected iDCs. To discriminate iDC populations with different 
surface density of gE after VZV infection the marker M1 and M2 were used. (B) The percentage of DCs 
expressing gE weakly (M1) or strongly (M2) for each DC population after infection with the VZV strain V-
Oka and JoSt are shown (n=7; error bars are SD).  
 
3.6 Phenotypic Changes of CD1 Molecules on VZV-infected iDCs 
Recently, a case report sparked the interest on CD1 antigen presentation in the context of 
VZV infection. The report demonstrated a patient with a deficiency in Natural Killer T (NKT) 
cells who developed disseminated varicella after vaccination with the V-Oka strain
26
. NKT 
cells recognize lipid antigen through CD1d molecules. Therefore, the impact of VZV infec-
tion on CD1 antigen presentation on iDCs was assessed. For this purpose, VZV-infected iDCs 
2d p.i. were stained for CD1a, CD1b, CD1c (group 1) and CD1d (group 2) molecules and 
analyzed by flow cytometry (Fig. 21a).  
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Fig. 21: Phenotypic changes in CD1 expression on VZV-infected iDCs (2d p.i.).  
(a) Histogram plots show surface expression of CD1a, CD1b, CD1c and CD1d with indicated mean fluo-
rescence intensities (MFI). One representative experiment out of six or more is shown. (b) Box-Whisker-
Plot of MFI of CD1c surface expression on mock, V-Oka and JoSt infected iDCs (n=16). P values < 0.05 
were considered significant.  
No changes in CD1a, CD1b and CD1d expression on iDCs were observed after VZV in-
fection compared to the mock control (Fig. 21a). Intriguingly, cell surface expression of 
CD1c was significantly enhanced on both V-Oka (P=0.0002) and JoSt (P=0.009) infected 
iDCs compared to the mock control (Fig. 21b). To rule out that this increase was due to 
enhanced transcription, quantitative real-time PCR analyses of VZV-infected iDCs were per-
formed (Fig. 22). Analysis of group 1 CD1 transcripts pointed out that VZV infection did not 
interfere with the transcription of group 1 CD1 molecules. Therefore, the cell surface ex-
pression of CD1c on iDCs seems to be modulated on the protein level by VZV. 
 
Fig. 22: Analysis of group 1 CD1 transcripts in VZV-infected iDCs.  
The abundance of mRNA encoded by group 1 CD1 genes was determined by quantitative real-time PCR. 
The values are given relative to uninfected iDCs. The fold induction of transcripts in VZV-infected iDCs 
relative to transcripts in uninfected iDCs (stippled line) is shown. Data are delineated from three inde-
pendent experiments (error bars are SD). 
55 
Altogether, these data provide evidence that lipid antigen presentation through CD1c 
is influenced by VZV and might have a functional impact on the reciprocal interaction of 
iDCs and T cells. Additionally, no differences between the vaccine and a clinical isolate of 
VZV regarding the infection efficiency of iDCs and their phenotypic changes could be fig-
ured out. 
 
3.7 Impact of VZV induced CD1c Upregulation on Innate  γδ T Lymphocytes  
To study the functional impact of VZV induced CD1c upregulation, cytotoxicity and cytokine 
secretion assays with a well-characterized CD1c-restricted γδ T cell line were performed. 
Recently, it was shown that these γδ T cells recognize a yet unknown self-lipid in the con-
text of CD1c
131
.  
The cytotoxic potential of γδ T cells was assessed by detecting the degranulation of T 
cells which was shown to be essential for perforin-mediated killing
171
. CD107a (Lamp-1) is a 
lysosomal protein which is normally found within the cytotolytic granulas of T cells and is 
detected on the cell surface of T cells after degranulation. Therefore, CD107a staining on T 
γδ T cells was verified to test cytotoxic activity (Fig.23). Spontaneous degranulation on γδ T 
cells could be observed but was less than 5% (Fig. 23b). In contrast, in the presence of 
mock, V-Oka and JoSt infected iDCs up to 30% of CD1c-restricted γδ T cells degranulated. 
However, no differences between the mock and VZV-infected iDCs could be detected.  
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Fig. 23: Degranulation of CD1c-restricted γδ T cell stimulated with VZV-infected iDCs. 
γδ T cells were cultured alone (-) or in the presence of mock, V-Oka or JoSt infected iDCs for 6h and 
stained for γδTCR and CD107a expression and analyzed by flow cytometry. (a) Dot plot showing the per-
centage of γδTCR and CD107a positive cells. One representative experiment of five is shown. (b) Mean of 
percentages of CD1c-restricted γδ T cells expressing CD107a (n=5; error bars are SD). 
Furthermore, the activation of γδ T cells was assessed by detection of secreted IFN-γ 
in the presence of mock or VZV-infected iDCs (Fig. 24). These assays were carried out with 
clinical isolates of different VZV genotypes to rule out a genotype dependent interference 
of VZV with γδ T cell activation (Fig. 24a).   
 
Fig. 24: IFN-γ secretion of CD1c-restricted γδ T cells in the presence of mock or VZV-infected iDCs.  
(a) Secreted IFN-γ was detected in the supernatant of mock or VZV-infected iDCs in the absence or pres-
ence of CD1c-restricted γδ T cells by ELISA (48h) (n=5; error bars are SD). (b) Box-Whisker-Plot of statis-
tical analysis of secreted IFN-γ by CD1c-restricted γδ T cells in the presence of mock, V-Oka or JoSt in-
fected iDCs (n=6). P value < 0.05 was considered to be significant.  
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Immature DCs infected with the vaccine strain V-Oka could activate γδ T cells to se-
crete high amounts of IFN-γ. In striking contrast, iDCs infected with clinical isolates regard-
less of their genotype failed to activate CD1c-restricted γδ T cells. The IFN-γ secretion by γδ 
T cells in the presence of iDCs infected with the virulent strain JoSt (P=0.031) was signifi-
cantly inhibited compared to V-Oka infected iDCs (Fig. 24b). 
CD1c-restricted γδ T cells were cocultured with mock or VZV-infected iDCs in the 
presence of a blocking antibody directed against CD1c or the respective isotype control to 
verify the specificity for CD1c (Fig. 25). Anti-CD1c antibodies but not the respective isotype 
control could block IFN-γ secretion.  
 
Fig. 25: Restriction of γδ T cells for lipid antigen presentation through CD1c.  
Mock or VZV-infected iDCs were cocultured with γδT cells for 48h in the presence of anti-CD1c antibodies 
or the respective isotype control (20 µg/ml). Secreted IFN-γ was measured in the supernatant by ELISA.  
Next, the possibility that the observed functional differences were due to differences 
in apoptotic death of iDCs infected with VZV was assessed. For this purpose iDCs were 
stained by AnnexinV and propidium iodide (PI) and analyzed by flow cytometry (Fig. 26).  
 
Fig. 26: Detection of apoptotic death on mock or VZV-infected iDCs 2d post VZV infection.  
Immature DCs were double stained by AnnexinV and propidium iodide (PI). Numbers indicate the per-
centage of cells within each quadrant. One representative experiment out of three is shown. 
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In mock-infected iDCs only very low percentages of apoptotic cells could be detected 
(Fig. 26 and Table 1). In strong contrast, in all VZV-infected iDCs induction of apoptosis 
could be observed. Interestingly, no differences were seen in the vaccine-infected iDCs 
compared to iDCs infected with VZV clinical isolates (Table 11).  
Tab. 11: Analysis of apoptotic death in iDCs.  
The percentages of single-positive (AnnexinV) or double-positive (AnnexinV and PI) cells after mock in-
fection (n=5), infection with V-Oka or JoSt (n=5) and with the genotypes M1, E2 and E1 (n=3) are summa-
rized. The mean percentage and SD are shown. 
 % single positive iDCs  
(AnnexinV) 
% double-positive iDCs  
(AnnexinV and PI) 
mock 2.46 ± 0.69  0.99 ± 0.38 
V-Oka 21.23 ± 4.64 3.00 ± 1.43 
JoSt 18.51 ± 3.28 2.81 ± 1.21 
M1_935/05 16.03 ± 6.69 2.02 ± 1.80 
E2_769/05 17.92 ± 4.73 2.67 ± 1.93 
E1_667/05 17.07 ± 3.94 2.61 ± 1.81 
Recently, it was shown that VZV is transmitted from infected iDCs to T cells resulting 
in productive T cell infection
20
. Furthermore, it was demonstrated that T cells infected with 
measles virus, a member of the Paramyxoviridae, are functionally impaired. Therefore, it is 
possible that VZV alters the function of γδ T cells after transmission from infected iDCs to 
γδ T lymphocytes. To test whether transmission of VZV was different for the vaccine strain 
V-Oka and the clinical isolate JoSt, γδ T cells were stained for the expression of gE and the 
γδ-T cell receptor (TCR) and analyzed by flow cytometry (Fig. 27).  
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Fig. 27: Transmission of VZV from iDCs to γδ T cells.  
(a) 2d p.i. VZV-infected iDCs were cocultured for 48h with CD1c-restricted γδ T cells and analyzed by flow 
cytometry. Due to differences in cellular size (FSC-H) and granularity (SSC-H) γδ T cells are distinguishable 
from iDCs. (b) Transmission of VZV was assessed by dual staining of gated γδ T cells for the expression of 
viral gE and the γδ-T cell receptor (TCR). Indicated numbers represent the percentage of cells within the 
quadrant. One representative experiment of five is shown.  
Due to differences in cellular size (FSC-H) and granularity (SSC-H) γδ T cells could be 
separated from iDCs by setting a scatter gate and analyzing for surface expression of γδ-T 
cell receptor (TCR) and viral gE (Fig. 27a). More than 75% of the gated cells were positive 
for the γδ-TCR (Fig. 27b). Co-expression with gE is shown for one representative experi-
ment (Fig. 27b). In five independent experiments 16.8% ± 10.1% (mean ± SD) γδ T cells in 
the presence of V-Oka infected iDCs expressed gE on the cell surface. In the presence of 
JoSt infected iDCs 20.5% ± 11.5% (mean ± SD) γδ T cells showed gE cell surface expression. 
Thus, no differences in the transmission rate from iDCs to γδ T cells were detected for the 
vaccine strain V-Oka and the clinical isolate JoSt. Both VZV strains infected T cells at only 
low rates in line with previously published observations
174
. 
Next γδ T cells were stimulated with the lectin phytohaemagglutinin (PHA) in the 
presence of VZV-infected iDCs to test whether VZV rendered γδ T cells functionally inert. 
PHA was used to activate T cells independently of the presented ligand and co-stimulatory 
signals.  
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Fig. 28: Functional integrity of γδ T cells.  
Detection of secreted IFN-γ of PHA stimulated γδ T cells in the presence of mock or VZV-infected iDCs. 
One representative experiment of three is shown. 
IFN-γ secretion of γδ T cells was fully restored in the presence of iDCs infected with the 
clinical isolate JoSt after stimulation with PHA (Fig. 28). Altogether, these data provide 
evidence that the observed functional differences are due to the interference of VZV 
with DC function.  
 
3.8 Instruction of VZV-infected iDCs by CD1c-restricted γδ T cells  
A hallmark of DC biology is their potential to differentiate from highly phagocytotic antigen 
capturing iDC into powerful T cell stimulating mDC. This differentiation process can be in-
duced by microbial stimuli, cytokines or by innate lymphocytes. Recently, it could be dem-
onstrated that self-reactive CD1-restricted αβ and γδ T can promote DC maturation in the 
absence of foreign antigens, a process which is called DC instruction
72,73
.  
An important aim of this thesis was to investigate whether γδ T cells can license VZV-
infected iDCs to mature. For this purpose, iDCs were stained for cell surface expression of 
the maturation marker CD83 and CD86 after coculture with γδ T cells (Fig. 29). LPS stimu-
lated DCs were included as a positive control in the experimental setting. Immature DCs 
infected with the V-Oka or the clinical isolate JoSt alone expressed only low amounts of 
CD83 and CD86. In contrast coculture with γδ T cells or stimulation with LPS induced full 
maturation of VZV-infected iDCs as shown by high expression of CD83 and CD86. 
Interestingly, in this type of analysis no differences were observed for the vaccine strain V-
Oka and the clinical isolate JoSt indicating that both V-Oka and JoSt did not interfere with 
phenotypic maturation.  
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Fig. 29: Phenotypic analysis of surface expression of CD83 and CD86 on iDCs.  
Flow cytometry analysis of surface expression of (a) CD83 and (b) CD86 on iDCs alone (-), after instruc-
tion by γδ  T cells or after stimulation with LPS (48h). Numbers within the histogram plots represent 
percentage of positive cells (a) or mean fluorescence intensities (MFI) (b). One representative experi-
ment of three is shown.  
Functional maturation of iDCs leads to secretion of IL-12 which drives the subse-
quent T cell response of CD4
+
 T helper cell into the TH1 direction
175
. Therefore, we quanti-
fied bioactive IL-12 (IL-12p70) within the supernatant of VZV-infected iDCs in the absence 
or presence of CD1c-restricted γδ T cells (Fig. 30). Interestingly, VZV infection of iDCs did 
not lead to secretion of bioactive IL-12 (Fig. 30a). However in the presence of γδ T cells 
iDCs infected with the vaccine strain V-Oka were fully licensed to secrete bioactive IL-12. In 
strong contrast, iDCs infected with clinical isolates of VZV inhibited the secretion of IL-12 
regardless of their genotype. To evaluate the impact of IL-12 on IFN-γ secretion, γδ T cells 
and VZV-infected iDCs were cocultured in the absence or presence of neutralizing anti-IL-12 
antibodies and IFN-γ secretion was quantified by ELISA (Fig. 30b). Neutralization of the 
secreted IL-12 blocked more than 50% of IFN-γ secretion by γδ T cells.  Therefore, it seems 
likely that iDCs infected with clinical isolates of VZV have an intrinsic defect to produce 
bioactive IL-12 which in turn lacks to fully support the reciprocal production of IFN-γ by 
cocultured γδ T cells.  
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Fig.30: Disruption of IL-12 secretion in iDCs infected with clinical isolates of VZV.  
(a) Secretion of bioactive IL-12p70 by mock or VZV-infected iDCs (2d p.i.) cultured in the absence or 
presence of CD1c-restricted γδ T cells was quantified by ELISA after 48 h. One representative experiment 
of two is shown. (b) Secretion of IFN-γ was quantified after 48 h of coculture of mock- or VZV-infected 
iDCs and γδ T cells without (w/o) or in the presence of neutralizing anit-IL12 antibodies. One representa-
tive experiment of two is shown.  
A powerful inducer of IL-12 secretion by iDCs is the ligation of CD40 on DCs by its  
CD40 ligand (CD40L) on T cells
175
. Signaling through CD40 activates the mitogen–activated 
protein kinase (MAPK) pathway, which leads to phosphorylation of c-Jun N-terminal 
kinases (JNK), extracellular signal-regulated kinases (ERK) and p38 mitogen-activated pro-
tein kinases (p38) and finally to IL-12 gene transcription
176
. The lack of IL-12 secretion by 
iDCs infected with clinical isolates of VZV provides evidence that VZV might interfere with 
the IL-12 signaling pathway. Therefore, the signal through CD40 on iDCs was provided in 
trans by coculture with a cell line which stable expressed CD40L on their cell surface
168
. 
Mock- or VZV-infected iDCs were left unstimulated or stimulated with CD40L and the ly-
sates were analyzed by immunoblotting (Fig. 31). LPS-stimulated DCs were used as a posi-
tive control. 
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Fig. 31: Activation of the MAPK pathway in VZV-infected iDCs.  
LPS-stimulated, mock, V-Oka and JoSt infected iDCs were cultured in the absence (-) or presence of 
CD40L for 15 min. Subsequently, phosphorylated MAP-kinases (p-JNK, p-ERK and p-p38) and total 
amounts of MAP-kinases (JNK, ERK and p38) were analyzed by western blot. VZV infection was detected 
by expression of viral glycoprotein E (gE) and ß-actin was used as loading control. One representative 
experiment out of three is shown. 
Phosphorylation of the MAP-kinases JNK and ERK was detected only in LPS stimu-
lated iDCs (Fig. 31). However, low levels of phosphorylated p38 were also observed in 
mock, V-Oka and JoSt infected iDCs. In contrast, in the presence of CD40L-expressing cells 
phosphorylation of all three kinases was detectable in lysates of mock, V-Oka and JoSt in-
fected iDCs. In conclusion, no intrinsic defect within the MAPK pathway could be observed 
in iDCs infected with the clinical isolate JoSt.   
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Secretion of IL-12 by iDCs infected with the clinical isolate JoSt was tested in the 
presence of a strong CD40L signal in trans to investigate whether these cells have an intrin-
sic defect (Fig. 32). Interestingly, JoSt-infected iDCs secreted as much IL-12 as vaccine-
infected iDCs after stimulation with CD40L.   
 
Fig. 32: CD40-mediated rescue of IL-12 secretion in JoSt infected iDCs.  
iDCs were left unstimulated (-) or stimulated with CD40L-expressing cells for 48h and secretion of bioac-
tive IL-12p70 was quantified by ELISA in the supernatant. One out of three independent experiments 
done in triplicate is shown (error bars are SD).  
As IL-12 is essential for inducing IFN-γ production by T cells, CD1c-restricted γδ T cells 
were added to the system and IFN-γ was quantified by ELISA in the supernatant (Fig. 33). In 
this way the ability of JoSt-infected iDCs to stimulate IFN-γ secretion by γδ T cells was fully 
rescued.  
 
Fig. 33: CD40-mediated restoration of IFN-γ secretion by γδ T cells.  
iDCs were left unstimulated (-) or stimulated by CD40L-expressing cells and secretion of IFN-γ by γδ T 
cells was quantified. One out of four independent experiments done in triplicates is shown (error bars 
are SD). 
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Collectively, these data suggest that iDCs infected with virulent VZV strains cannot 
induce CD1c-restricted γδ T cells to provide adequate CD40 signaling. In turn, lack of IL-12 
secretion results in low IFN-γ secretion by T lymphocytes. 
 
3.9 Interference of VZV with the Co-Stimulatory Capacity of DCs  
As co-stimulation through CD40 and CD86 on DCs is essential for full T cell activation
89
, cell 
surface expression of CD40 and CD86 on VZV-infected iDCs was investigated (Fig. 34 and 
35). Flow cytometry analysis showed a significant increase in CD40 cell surface expression 
on iDCs infected with the vaccine V-Oka (P=0.002) compared to mock-infected iDCs and to 
JoSt infected iDCs (P=0.01) (Fig. 34).  
 
Fig. 34: Increase in CD40 expression on iDCs infected with the vaccine V-Oka.  
(a) Histogram analysis of CD40 expression on mock, V-Oka and JoSt infected iDCs (2d p.i.). Mean fluores-
cence intensities (MFI) are indicated and are representative for 11 experiments. (b) Box-and-Whisker-
Plot of MFI on CD40 of mock, V-Oka or JoSt infected iDCs 2d p.i. (n=11). P values < 0.05 were considered 
to be significant. 
Additionally, analysis of CD86 expression on VZV-infected iDCs revealed that infection 
with the vaccine V-Oka induced a significant upregulation (P=0.002) compared to iDCs 
infected with the clincial isolate JoSt (Fig. 35).  
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Fig. 35: Significant increase in CD86 expression on V-Oka infected iDCs.  
(a) Histogram analysis of CD86 expression on mock, V-Oka and JoSt infected iDCs (2d p.i.). Mean fluores-
cence intensities (MFI) are indicated and are representative for 10 experiments. (b) Box-and-Whisker-
Plot of MFI on CD86 expression on mock, V-Oka or JoSt infected iDCs 2d p.i. (n=10). P value < 0.05 was 
considered to be significant. 
Quantitative real-time PCR analysis was used to investigate whether the observed 
failure of JoSt-infected iDCs to upregulate CD40 and CD86 was due to interference on the 
transcriptional level. As shown in figure 36, VZV did not significantly modulate CD40 and 
CD86 gene expression compared to mock-infected iDCs.  
 
Fig. 36: Analysis of CD40 and CD86 transcripts in VZV-infected iDCs.  
The abundance of mRNA encoded by CD40 and CD86 genes was determined by quantitative real-time 
PCR. The values are given relative to uninfected iDCs. The fold induction of relative transcripts in VZV-
infected iDCs relative to transcripts in uninfected iDCs (stippled line) is shown. Data are delineated from 
three independant experiments (error bars are SD). 
   The reciprocal crosstalk of DCs and T cells is not only regulated by co-stimulatory 
signals but also influenced by the expression of co-inhibitory molecules which trigger T cell 
responses
82
. Enhanced expression of molecules of the B7-family on DCs has been shown to 
silence T cell responses by interaction of B7-H1 or B7-DC molecules with Programmed 
Death 1 (PD-1) or of B7-H2 molecules with Inducible T-cell Co-Stimulator (ICOS). Therefore, 
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the expression of co-inhibitory molecules of the B7-family on VZV-infected iDCs was inves-
tigated by flow cytometry (Fig. 37). 
 
 
Fig. 37: Expression of co-inhibitory molecules of the B7 family on VZV-infected iDCs.  
Histogram analysis of B7-DC, B7-H1, B7-H2, B7-H3 and B7-H4 (black curves) expression on mock, V-Oka 
and JoSt infected iDCs (2d p.i.). Curves in gray represent isotype control. Mean fluorescence intensities 
(MFI) are indicated.  
However, no induction of co-inhibitory molecules of the B7-family could be detected 
on VZV-infected iDCs. Therefore, it is unlikely that the observed defect in IFN-γ secretion by 
γδ T cells in the presence of iDCs infected with virulent strains of VZV was due to inhibitory 
signaling. 
 
3.10 Block of TLR2 Signaling by Virulent VZV 
Synergistic effects of PRR signaling are particularly important for the production of bioac-
tive IL-12
68,70,177
. TLR2 has been shown to play a role in detection of herpesviruses including 
HSV, HCMV and VZV
178-182
. Therefore, we tested whether virulent VZV can interfere with 
TLR2 signaling. VZV-infected iDCs were stimulated through TLR2 with lipoteichoic acid (LTA) 
and subsequent IL-12p70 production was assessed. Moreover, to address the question if 
viral replication interferes with TLR signaling we compared iDCs infected with replication 
competent virus with that stimulated with UV inactivated virus. Additionally, HSV was in-
cluded in the experimental setting to investigate if any of the observed effects are common 
to alpha-herpesviruses.  
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Viral infection of iDCs did not lead to secretion of IL-12 by iDCs (Fig. 38). However, 
additional stimulation with LTA provoked secretion of high amounts of IL-12 by iDCs in-
fected with the vaccine strain V-Oka and HSV. In strong contrast, iDCs infected with the 
clinical isolate JoSt blocked IL-12 secretion suggesting a VZV specific interference with TLR2 
signaling. Stimulation of iDCs with UV inactivated virus did not induce IL-12 secretion. Inte-
restingly, further stimulation with LTA only induced low amounts of IL-12p70. These data 
provide evidence that active viral replication was critical to prime iDCs for further PRR trig-
gering with subsequent secretion of bioactive IL-12. Moreover, these data demonstrate 
that virulent VZV efficiently blocked TLR2 stimulation in contrast to the vaccine strain V-
Oka and HSV.   
 
 
Fig. 38: Virulent VZV blocks TLR2 signaling in mo-DCs.  
Immature DCs were left untreated (-), mock, V-Oka, JoSt or HSV infected (virus) or stimulated with UV-
inactivated virus (UV virus) for 2d. Thereafter, DCs remained unstimulated or were stimulated with TLR2 
agonist lipoteichoic acid (LTA) for 48h and IL-12p70 secretion was quantified by ELISA. One representa-
tive experiment out of two is shown (error bars are SD). 
 
In summary, myeloid CD11c
+
 DCs strongly infiltrated in skin lesions of herpes zoster 
patients. Ex vivo isolated cutaneous DCs were permissive to VZV infection and no differ-
ences in the infection efficiency between the vaccine strain V-Oka and virulent strain JoSt 
was observed. Similarly, monocyte-derived iDCs reflecting myeloid-derived inflammatory 
DCs were efficiently infected by both VZV strains without differences in the infection effi-
ciency. Although both the vaccine strain V-Oka and the virulent strain JoSt upregulated 
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CD1c, only V-Oka could efficiently induce IFN-γ secretion by CD1c-restricted γδ T cells. The 
observed failure of JoSt-infected iDCs to stimulate γδ T cells was neither due to an intrinsic 
functional defect of γδ T cells nor due to the upregulation of inhibitory molecules of the B-
7 family on the surface of iDCs. Furthermore, the CD40L-induced signaling pathway leading 
to subsequent IL-12 production was not disturbed in VZV-infected iDCs. Virulent VZV rather 
blocked TLR2 signaling within iDCs thereby inhibiting secretion of bioactive IL-12.  
Thus, the observed findings provide evidence that virulent VZV strains successfully inter-
fere with functional maturation of iDCs by blocking efficiently TLR2 signaling thereby pre-
venting stimulation of subsequent innate immune responses. This newly discovered im-
mune evasion strategy explains why virulent VZV strains successfully replicate within the 
skin thereby causing the typical rash.  
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4 Discussion 
 
Skin tropism of VZV is responsible for the most obvious clinical manifestation of VZV infec-
tion producing the vesicular cutaneous lesions that are associated with varicella and her-
pes zoster. Primary infection of VZV is characterized by infection of epithelial cells and DCs 
of the respiratory mucosa, viral transmission to T cells and subsequent viremic phases. 
Thereafter, the virus is transported to the skin, the major replication site of VZV. After a 
prolonged incubation time of 10 to 21 days the typical vesicular lesions appear
183
. It is as-
sumed that this prolonged period represents the time required for VZV to overcome un-
recognized but potent innate antiviral immune responses within the skin
184
.  
Until to date three different immune evasion mechanisms have been elucidated to be in-
volved in VZV pathogenesis
183
. First, it has been demonstrated that the serine/threonine 
kinase ORF66 is responsible for downregulation of cell surface MHC class I molecules on 
fibroblasts by retaining them within the golgi compartment and accelerating their degrada-
tion
120
. In addition, VZV inhibits IFN-γ mediated upregulation of cell surface MHC class II 
molecules on fibroblasts
122
. This escape strategy could limit primary sensitization of CD4
+
 T 
cells to VZV peptides and delay the early amplification of VZV-specific CD4
+
 helper T cells 
and the release of cytokines at cutaneous sites of VZV replication. As third immune evasion 
mechanism the interference with phenotype and function of mDCs was discovered
118
. Al-
together, these observations underline that VZV evades adaptive T cell response by delay-
ing clonal expansion of VZV specific CD4
+
 and CD8
+
 T lymphocytes.  
However, detailed analysis of the interplay of VZV with cells involved in cutaneous 
immunity has never been investigated so far. Most importantly, immunological responses 
explaining the different clinical outcome of infection with the vaccine and virulent strains 
of VZV remain to be elucidated.  
 
4.1 Role of Cutaneous DCs in VZV Pathogenesis 
The skin as major immune organ of the human body contains a variety of immune cells 
including epidermal LCs, DDCs and intraepithelial γδ T cells. It is postulated that VZV-
infected T cells transport the virus during the viremic phase to skin epithelial cells which 
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are subsequently infected by the virus
20
. It was shown in the SCID-hu mouse model that 
VZV replication in epithelial cells is associated with expression of a gene product that inhi-
bits antiviral IFN-α production in foci of infected cells by interfering with Stat1 activation
28
. 
In the surrounding non-infected area increased levels of IFN-α could be detected. However, 
which immune cells in the skin are targeted by VZV has not been investigated so far.  
LCs and DDCs are migratory DCs which are the main DC subtype in the steady-state. 
In contrast, inflammatory DCs transiently occur during an ongoing infection. Therefore, skin 
sections of herpes zoster patients were analyzed for these DC subtypes. Immunofluores-
cence microscopy analysis showed the disappearance of epidermal CD1a and Langerin 
expressing LCs. This can be explained by the emigration of LCs to local lymph nodes where 
they might transfer the captured antigen to resident DCs. This was recently demonstrated 
in HSV-1 infected mice suggesting an important role of migratory DCs which emigrate from 
infected skin to local lymph nodes and transfer captured antigens to resident CD8
+ 
DCs 
which in turn activate CD8
+
 T cells
94,104
. On the other hand, migratory submucosal DCs but 
not LCs were shown to induce a protective TH1 response in mice after vaginal infection with 
HSV-2
106
. In sharp contrast to LCs, a strong infiltration of DCs of myeloid origin expressing 
CD11c, CD1c, CD1b, CD206 and CD209 in close proximity to virion containing vesicles was 
observed. Recently, it was demonstrated that monocytes recruited to the dermis during 
Leishmania infection locally differentiate into “dermal monocyte-derived DCs” and induce 
protective TH1 responses
96
. Therefore, it seems likely that the observed infiltrated myeloid-
derived DCs in herpes zoster lesions are inflammatory DCs derived from monocytes. Inte-
restingly, a strong infiltration of CD11c negative pDCs was detected in vesicular lesions of a 
varicella biopsy
107
. We did not stain for a specific marker of pDCs, but it is possible that 
different subtypes of DCs play diverse roles during systemic varicella infection or reactiva-
tion during herpes zoster.  
Despite the strong infiltration of CD3 positive T cells in herpes zoster skin, detection 
of the intraepithelial γδ T cells within herpes zoster lesions failed. This might be due to a 
detection limit of the antibody used. On the other side it is possible that intraepithelial 
Vδ1
+ 
γδ T cells as innate immune cells emigrated early to local lymph nodes to stimulate 
other immune cells. A protective role for intraepithelial Vδ1
+ 
γδ T cells in HSV-2 infection 
was recently demonstrated in γδ T cell depleted mice
185
.  
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The percentage of γδ T cells in blood of herpes zoster patients was not significantly 
altered compared to percentages of healthy control donors. It has to be mentioned, that it 
is unlikely that Vγ9δ2 T cells the major subset in peripheral blood are influenced during 
reactivation of VZV. However, it would be interesting to investigate the γδ T cell population 
during systemic varicella infection where several viremic phases occur. Especially for Vγ9δ2 
T cells it has been shown that they acquire the ability to function as professional APCs for 
naive αβ T cells
159
. Furthermore, cross-presentation of microbial and tumor antigens by 
activated Vγ9δ2 γδ T cells to CD8
+
 αβ T cells has been described
160
.  
In the SCID-hu mouse model the role of T cells as transport vehicle for viral spread 
during VZV pathogenesis was revealed
186
. Moreover, in this study the vaccine showed de-
creased replication in the skin compared to clinical isolates of VZV. However, vaccine strain 
V-Oka and virulent strains of VZV do not differ in the replication efficiency in human cell 
lines. This finding of our study was also observed by other research groups and suggests 
that cutaneous immune cells might be responsible for the observed failure of the vaccine 
strain to replicate efficiently in the SCID-hu mouse model. Furthermore, this hypothesis is 
in line with the observed finding that vaccinees do not suffer from the typical VZV rash 
whereas naive persons infected with clinical isolates of VZV develop disseminated varicella. 
Several scenarios are possible which might explain the potency of virulent VZV strains to 
replicate efficiently in the skin. First, it is possible that only virulent VZV strains possess the 
capacity to infect cutaneous immune cells and modulate their immune function thereby 
silencing early antiviral immune responses. Next, it is conceivable that both the vaccine 
and virulent VZV strains infect efficiently cutaneous immune cells but only virulent VZV 
strains interfere with their immune function. To test these hypotheses epidermal LCs and 
DDCs were isolated from human skin and tested for their permissivity to VZV infection and 
subsequent phenotypic changes. LCs and DDCs isolated from human skin reflecting conve-
tional DCs during steady-state conditions were both permissive to VZV infection and no 
difference in the infection efficiency between both DC types was observed. More impor-
tantly, the vaccine strain V-Oka and the clinical isolate JoSt could infect these immunologi-
cal important cell types equally well. Interestingly, VZV infection did not induce phenotypic 
maturation of LCs and DDCs as low cell surface expression of CD83 and CD86 was ob-
served. Moreover, a decrease in cell surface expression of CD40 was detected on VZV-
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infected LC and DDCs. Thus, both vaccine strain V-Oka and clinical isolate JoSt infect cuta-
neous DCs but only weakly modulate their phenotype. 
 
4.2 VZV-induced Increase in CD1c Expression on Monocyte-Derived iDCs 
The detected infiltration of myeloid CD11c
+
 DCs in herpes zoster lesions suggests a role for 
transiently occurring inflammatory DCs in the immune response against VZV. Therefore, 
iDCs derived from monocytes through differentiation with IL-4 and GM-CSF in vitro were 
used for further investigations as they reflect inflammatory DCs transiently occurring dur-
ing an ongoing infection (Ardavin C. personal communication).  
In contrast to the low infection rates of LCs and DDCs, almost all iDCs were infected 
by the vaccine strain V-Oka and the clinical isolate JoSt. Importantly, as observed for LCs 
and DDCs no differences in the infection efficiency between both viral strains were de-
tected. It was shown by A. Abendroth that infection of iDCs by a virulent VZV strain was not 
accompanied by phenotypic changes in MHC class I, MHC class II, CD86, CD40 and CD1a 
cell surface expression
20
. It has to be mentioned that in this study the infection efficiency 
of virulent VZV was markedly lower (34.4% ± 6.6%; mean ± SEM). Moreover, no investiga-
tions were performed with the vaccine strain V-Oka. An aspect of our work was to assess 
the impact of VZV infection on CD1 antigen presentation as deficiency in CD1-restricted 
NKT cells has been associated with disseminated varicella after vaccination with the V-Oka 
strain
26
. Interestingly, cell surface expression of CD1c was significantly enhanced after in-
fection with both the vaccine strain V-Oka and the clinical isolate JoSt compared to mock-
infected iDCs. However, CD1a, CD1b and CD1d cell surface expression remained unaltered. 
The low CD1d cell surface expression can be explained by the fact that cultivation was per-
formed with fetal calf serum which was recently demonstrated to favor group 1 CD1 ex-
pression (CD1a, CD1b and CD1c) over group 2 (CD1d) expression in contrast to human se-
rum
187
. Additionally, it is well documented that monocyte-derived iDCs express only very 
low amounts of cell surface CD1d compared to monocytes
188
. Antigen presentation 
through CD1c was shown to be important in T cell mediated recognition of Mycobacterium 
tuberculosis infections
128,129
. Furthermore, clinical investigations of leprosy lesions provide 
evidence that the clinical outcome of this disease is determined by the CD1 antigen pre-
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senting system
133
. This study has demonstrated a strong induction of group 1 CD1 proteins 
in dermal granuloma of skin biopsies from patients with the tuberculoid form of leprosy 
which correlates with active cellular immunity to Mycobacterium leprae. In contrast, in 
lesions from patients with the lepromatous form no induction of group 1 CD1 proteins was 
observed. These patients are characterized by lack of effective cellular immunity to Myco-
bacterium lepra. Quantitative real-time PCR analyses were performed to investigate if the 
observed increase in cell surface expression of CD1c on VZV-infected iDCs was regulated on 
the transcriptional or protein level. No increase in relative transcripts of CD1a, CD1b or 
CD1c in VZV-infected iDCs could be detected. Thus, VZV modulates CD1c cell surface ex-
pression on the protein level. This is in line with the fact that HSV-1, KHSV, HIV-1 or HCMV 
interfere with CD1 antigen presentation on the protein level by inhibiting trafficking or 
recycling of CD1 molecules
189
. Therefore, it is likely that the VZV-induced increase in cell 
surface CD1c is due to increased trafficking of CD1c to the cell surface.  
 
4.3 Impact of VZV-induced CD1c Upregulation on Intraepithelial CD1c-restricted γδ 
T Cells 
To investigate the possibility if CD1c antigen presentation might play a role in the induction 
of cellular immunity to VZV functional analysis with a well characterized CD1c-restricted 
Vδ1
+
 γδ T cell clone was performed. Cytokine secretion assays showed a significant de-
crease in IFN-γ secretion by tissue specific CD1c-restricted γδ T cells in the presence of iDC 
infected with virulent VZV strains. This effect was independent of their genotype. In strong 
contrast, γδ T cells secreted high amounts of IFN-γ in the presence of iDCs infected with the 
vaccine strain V-Oka. IFN-γ secretion by γδ T cells was induced by antigen presentation 
through CD1c as demonstrated by blocking experiments. This functional difference was 
observed although both the vaccine strain and the VZV clinical isolate significantly in-
creased CD1c cell surface expression. The observed finding might be explained by presen-
tation of different lipid ligands through CD1c. As viruses hijack the host cell protein machi-
nery it is likely that they also modulate the lipid metabolism thereby altering lipid antigen 
presentation through CD1 molecules. It was recently shown that HCMV regulates the host 
cell sphingolipid metabolism to increase viral replication
190
. Additionally, it has been shown 
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that mammalian sphingolipids are presented by all CD1 molecules to CD1-restricted T 
cells
191
. Therefore, further investigations should address the capacity of virulent VZV strains 
to interfere with lipid biosynthesis pathways which might ensure replication within the 
skin. Elucidation of such a mechanism could provide new insight into the attenuation of 
VZV, thereby facilitating development of new strategies for future vaccine design.  
Blocking the activation of γδ T cells might be a novel immune evasion strategy of vi-
rulent VZV strains to ensure their replication and spread during primary infection and reac-
tivation. Interference with early IFN-γ secretion by innate γδ T cells may inhibit subsequent 
upregulation of MHC class II molecules on epithelial cells and fibroblasts which in turn lim-
its immune surveillance by CD4
+
 T cells. This is in line with the observed finding by Aben-
droth et al. that VZV infection of fibroblasts inhibited IFN-γ mediated induction of MHC 
class II cell surface expression by blocking transcription of interferon regulatory factor 1 
(IRF-1) and the MHC class II transactivator (CIITA)
122
. However, effective immune responses 
can be detected when the rash appears. PBMCs from varicella patients after the onset of 
rash secreted high amounts of IL-12, IFN-γ and TNF-α which inhibited the spread of VZV 
within fibroblasts
192
. This finding provides evidence that VZV interferes only transiently 
with early innate immune responses to facilitate viral spread.  
Many viruses including VZV posses T cell tropism. However, the observed defect in 
IFN-γ secretion by CD1c-restricted T cells was not due to different transmission rates from 
VZV-infected iDCs to γδ T cells. Low transmission rates of only ∼ 6% observed in this study 
are in line with low transmission rates found in another study using several VZV clinical 
isolates and viral mutants
174
. Addition of the lectin PHA to the coculture of γδ T cells and 
iDCs infected with virulent VZV fully restored IFN-γ secretion by T cells. Thus, VZV does not 
interfere with T cell function as it was shown for measles virus infection
193,194
.  
Furthermore, no differences in the cytotoxic potential of the CD1c-restricted γδ T 
cells could be observed. This might be explained by the fact that the detection of CD107a 
(Lamp-1) anchored in the cell membrane of cytotoxic granules on the cell surface is an ear-
ly event during degranulation of T cells and does not answer the question whether VZV-
infected iDCs were lysed efficiently. Therefore, the radioactive chromium release assay 
would be more appropriate to assess the lysis of the target cells. Unfortunately, this assay 
can not be performed in the Institute of Virology.  
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4.4 γδ T Cell mediated Instruction of VZV-infected iDCs 
The functional integrity of γδ T cells sparked the interest on the side of the DC. Immature 
DCs could be infected with the vaccine strain V-Oka or the clinical isolate JoSt to the same 
extent. Apoptotic death of VZV-infected iDCs was evaluated to exclude the possibility that 
fewer iDCs are present to activate γδ T cells. Intriguingly, induction of apoptosis in VZV-
infected iDCs could be detected. This is in line with reports showing induction of apoptosis 
in iDCs infected with HSV-1 and HCMV
114,195
. Importantly, no differences between the vac-
cine and any virulent strain of VZV could be observed. Virus-induced apoptosis represents 
an efficient means for providing non-infected bystander DCs with viral antigens for cross-
presentation to CD8
+
 T cells. Additionally, induction of apoptosis was observed in vitro in a 
VZV-infected subpopulation of PBMCs supporting our findings
196
.  
A hallmark of DC biology is their differentiation from an antigen sampling iDC into a 
potent antigen presenting mDC which activates T cells
59
. Recently, it has been demonstrat-
ed for both CD1-restricted αβ and γδ T cells that they can induce maturation of iDCs
72,73
. 
This T cell-mediated DC instruction has important implications for controlling subsequent 
polarization of acquired immunity. VZV infection of iDCs alone did not induce phenotypic 
and functional maturation of iDCs as only low cell surface expression of CD83 and CD86 
and no secretion of bioactive IL-12 (IL-12p70) was observed. In contrast, coculture with 
CD1c-restricted γδ T cells induced a fully mature phenotype of VZV-infected DCs with even 
higher expression of CD86 on VZV-infected iDCs compared to LPS-stimulated control DCs. 
Thus, CD1-restricted γδ T cells were able to phenotypically mature iDCs during an ongoing 
viral infection. Surprisingly, only vaccine-infected iDCs could be instructed functionally by 
CD1c-restricted γδ T cells to secrete bioactive IL-12. In strong contrast, functional instruc-
tion of iDCs infected with virulent VZV strains by γδ T cells failed (Fig. 40). This defect was 
independent of the VZV genotype used. So far this is the first description of a viral interfe-
rence with T cell mediated DC instruction.  
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Fig. 40: Scheme of γδ T cell-mediated instrunction of iDCs infected with virulent VZV.   
CD1c-restricted γδ T cells instruct VZV-infected iDCs to mature phenotypically, shown by cell surface 
expression of CD83 and CD86. However, functional instruction which results in secretion of bioactive IL-
12 failed in iDCs infected with virulent VZV strains.  
Neutralization experiments with anti-IL-12 antibodies revealed the positive feed-back 
loop between IL-12 secretion by DCs and IFN-γ secretion by T cells. Neutralization of se-
creted IL-12 by iDCs infected with the vaccine strain V-Oka reduced subsequent IFN-γ secre-
tion by CD1c-restricted γδ T cells providing evidence that IL-12p70 is critical for activation 
of γδ T cells. Moreover, this finding suggests that iDCs infected with virulent VZV strains are 
somehow intrinsically blocked to produce bioactive IL-12. The production of bioactive IL-12 
consisting of covalently linked p35 and p40 subunits is facilitated by stimulation through 
CD40L expressend on activated T cells
197
. Triggering of CD40 molecule on iDCs through 
CD40L expressed on T cells triggers the MAPK pathway leading to subsequent IL-12 produc-
tion
59,84
. However, VZV did not interfere with the activation of MAP kinases JNK, ERK and 
p38 which might have explained the deficiency in IL-12 secretion. This finding suggested 
that the interaction between CD40 on DCs and CD40L on T cells, which is required for in-
duction of IL-12 secretion, was interrupted. Indeed, by providing CD40L in trans by a 
CD40L-expressing cell line iDCs infected with the clinical isolate JoSt secreted as much IL-12 
as the vaccine-infected iDCs. Additionally, this rescue of IL-12 secretion also restored the 
secretion of high amounts of IFN-γ by γδ T cells in the presence of iDCs infected with the 
clinical isolate JoSt. Therefore, γδ T cells cocultured with VZV-infected iDCs were tested for 
upregulation of CD40L on the cell surface. Unfortunately, staining for cell surface expressed 
CD40L on γδ T cells failed. However, it has to be mentioned that staining for CD40L on T 
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cells is difficult due to its weakly expression in general. Therefore, a failure in upregulation 
of CD40L on γδ T cells cannot be excluded. On the other hand it is possible that a T cell 
stimulatory signal provided by the DCs is somehow abrogated by infection with virulent 
VZV.  
 
4.5 Co-Stimulatory and Inhibitory Molecules provided by VZV-infected iDCs 
The observed findings pointed out to have a closer look on cell surface expression of the 
co-stimulatory molecules CD40 and CD86 on VZV-infected iDCs. Interestingly, iDCs infected 
with the clinical isolate JoSt significantly inhibited cell surface expression of CD40 and CD86 
compared to vaccine-infected iDCs. This is in contrast to the finding observed on VZV-
infected LCs and DDCs where both viral VZV strains induced a decrease in cell surface ex-
pression of CD40. However, it has to be mentioned that monocyte-derived DCs resemble 
inflammatory DCs which transiently arise during inflammation, for example in skin lesions 
of herpes zoster patients. Therefore, it is likely that virulent VZV strains modulate the phe-
notype of this DC subset massively infiltrating the skin during ongoing viral replication. 
Furthermore, iDCs infected with virulent VZV still express abundant CD40 on the cell sur-
face which is probably sufficient to provide a T cell stimulating signal.  
Moreover, VZV-infected iDCs were stained for cell surface expression of co-inhibitory 
molecules of the B7-CD28 family
82
. Ligation through B7-DC and B7-H1 with programmed 
cell death (PD-1) on effector T cells or B7-H4 with B and T lymphocyte attenuator (BTLA) 
induces suppression of T cell activation. Recently, it could be demonstrated that in chroni-
cally infected HIV-1 and HCV patients B7-H1 was upregulated on myeloid derived DCs. This 
correlated with disease progression in HIV-1 and B7-H1 is a marker for chronic inflamma-
tion in HCV pathogenesis
198,199
. Therefore, selective upregulation of inhibitory molecules of 
the B7-family might explain the block in IFN-γ by γδ T cells in the presence of iDCs infected 
with virulent VZV strains. However, no upregulation of the above mentioned co-inhibitory 
molecules could be observed on VZV-infected cells. 
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4.6 Blocking TLR-2 Signaling in iDCs by Virulent VZV 
It has been demonstrated that production of bioactive IL-12 by DCs can be amplified by T 
cell derived signals, but must be initiated by innate signals
200
. Thus, CD40 ligation by T cells 
alone is not sufficient to induce IL-12p70 secretion by DCs. Signaling through PRRs is man-
datory for production of bioactive IL-12
201
. Recent findings give evidence that synergistic 
stimulation of TLRs is necessary to induce bioactive IL-12 production by DCs
68
. Further-
more, it has been demonstrated that stimulation of a single TLR favors IL-23 over IL-12 se-
cretion by myeloid-derived DC
68,69
. 
Recognition of pathogens by DCs is largely dependent on TLRs. Members of the TLR 
family have been shown to sense a variety of viruses by recognizing viral genomes within 
endosomes through TLR3 (double stranded RNA), TLR7, TLR8 (single stranded RNA), and 
TLR9 (CpG) or by recognizing viral structural components at the cell surface through TLR2 
and TLR4
66
. Especially, the TLR2 pathway has been shown to play an important role in sens-
ing herpesviral infections. Glycoproteins B and H of HCMV are directly recognized by TLR2 
and induce secretion of inflammatory cytokines through NF-κB in permissive cells
180,181
. 
Interaction of HSV-1 with TLR2 contributes to lethal encephalitis in mice which is depen-
dent on the adaptor molecule MyD88
178,179
. Moreover, it was shown that TLR2 is activated 
in monocytes in response to VZV infection
182
. Therefore, we tested the hypothesis if viru-
lent VZV targets TLR signaling in iDCs thereby blocking subsequent IL-12 production.  
Stimulation of iDCs with replication competent or UV-inactivated virus alone did not 
induce secretion of bioactive IL-12. By contrast, additional stimulation with TLR2 agonist 
LTA induced low levels of IL-12p70 in iDCs stimulated with UV-inactivated virus and much 
higher amounts of IL-12p70 in iDCs infected with the vaccine strain V-Oka or HSV. In sharp 
contrast, triggering TLR2 pathway in iDCs infected with clinical isolate JoSt induced only 
negligible amounts of IL-12p70 as observed with UV-inactivated virus. These findings dem-
onstrate that synergistic stimulation of different PRRs in iDCs is crucial to trigger bioactive 
IL-12 production. This is in line with reports describing strong synergistic effects of TLR li-
gands on IL-12 production by DCs
68
. Moreover, the data provide evidence that viral replica-
tion is essential to prime iDCs for further stimulation through TLRs as stimulation with UV-
inactivated virus is not sufficient for high IL-12 production. It has to be mentioned that UV-
light modifies viral genome which inhibits viral replication. However, the first steps of viral 
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life cycle comprising adsorption and penetration of virions into the host cell remained unal-
tered. Therefore, it is likely that a factor synthesized during viral replication of virulent VZV 
is responsible for blocking subsequent TLR2 signaling (Fig.41).  
 
Fig. 41: Scheme showing the interference of VZV with IL-12p70 secretion in iDCs.    
(a) The vaccine strain V-Oka primes DCs for further stimulation through TLR2 and CD40 which lead to 
subsequent IL-12p70 production. (b) In contrast, virulent VZV blocks TLR2 signaling thereby preventing 
bioactive IL-12 production. However, strong stimulation through CD40 by providing CD40L in trans pro-
mote IL-12 production. 
Interestingly, VZV-infected iDCs stimulated with LTA secreted higher amounts of bio-
active IL-12 as compared to iDCs after instruction by CD1c-restricted γδ T cells. Moreover, 
providing CD40L in trans induced the highest amount of IL-12p70 by VZV-infected DCs. 
These observations indicate that on the one hand CD1c-restricted γδ T cells stimulate VZV-
infected iDCs through CD40 only weakly. This might explain the difficulties to stain for 
CD40L on CD1c-restricted γδ T cells after coculture with VZV-infected iDCs by flow cytome-
try. Furthermore, the experiments with CD40L in trans revealed that the CD40-CD40L sig-
naling pathway was not disturbed in VZV-infected iDCs. However, stimulation of VZV-
infected iDCs with LTA showed that only virulent VZV blocks TLR2 signaling. It seems likely 
that virulent VZV interferes with a universal adaptor molecule involved in several TLR sig-
naling pathways. For example, TNF receptor associated factor 6 (TRAF6) which is involved 
in TLR2, TLR4, TLR5, TLR7, TLR8 and TLR9 signaling
66
.  
Bioactive IL-12 is a heterodimeric cytokine composed of covalently linked p35 and 
p40 subunits. Interestingly, the p40 subunit is also part of the cytokine IL-23 which is re-
quired for expansion and survival of TH17 cells.  Moreover, myeloid-derived DCs differen-
tially produce IL-23 and IL-12 in response to TLR agonists
69
. This study demonstrated that 
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several TLR agonists alone induce IL-23 expression, whereas multiple signals are required 
for commitment to IL-12 production. Furthermore, Peiser et al. demonstrated that LCs sti-
mulated through TLR2 acquired the capacity to polarize TH17 cells
202
. Therefore, it would 
be worth to investigate more closely the cytokine profile of VZV-infected iDCs after stimula-
tion through TLR2. It might be possible that virulent VZV blocks IL-12p35 secretion thereby 
favoring IL-23 over IL-12p70 production. 
Another research group has demonstrated that VZV activates inflammatory cytokines 
in human monocytes and macrophages via TLR2
182
. Primarily, it has to be mentioned that 
in this study the vaccine strain V-Oka was not included in the experimental setting allowing 
the comparatively validation of the TLR2 activating potential of VZV. Furthermore, only the 
secretion of IL-6 and IL-8 by human monocytes was assessed. Moreover, it was mentioned 
that active viral replication was not necessary for activation of NF-κB-driven reporter gene 
construct. Therefore, it might be possible that in this experimental setting a block in TLR2 
signaling by VZV could not be detected. 
Another important aspect is that viral replication is not sufficient to activate iDCs to 
secrete bioactive IL-12 but additional TLR stimulation is mandatory. This is in line with the 
general observed finding that live vaccines are more powerful inducers of immunity as 
compared to inactivated vaccines.  
Altogether, further investigations should address the question which adaptor mole-
cule in the TLR2 signaling pathway is blocked by virulent VZV strains compared to the vac-
cine. This might be a promising field which gives further insight in the pathogenicity of VZV 
strains and their potency to replicate successfully within the skin.  
In summary, these data provide evidence that virulent VZV strains prevent functional 
maturation of iDCs by blocking TLR2 signaling and bioactive IL-12 secretion. In turn early 
TH1 responses are prevented and thereby virulent VZV strains facilitate their replication 
and spread in the skin. In contrast, the vaccine strain V-Oka fully support functional matu-
ration of iDCs and subsequent activation of T cells. However, the molecular mechanisms 
underlying attenuation of the vaccine strain are not yet understood. Therefore, it might be 
worth to reveal the factor of virulent VZV strains which blocks TLR2 signaling. This finding 
has practical consequences as novel vaccination strategies have to verify that the candidate 
vaccines do not disrupt the dialogue between innate cells and DCs.  
82 
Finally, this finding might be of relevance for preventing herpes zoster in people with 
increasing age which show a decline in cell-mediated immunity that correlates with an in-
creased risk to develop herpes zoster. Several studies have shown that frequent exposure 
to circulating virulent VZV strains boost immunity to VZV and therefore reduces the risk for 
herpes zoster
52
. Promising vaccination studies with V-Oka as a zoster vaccine markedly re-
duced morbidity from herpes zoster and postherpetic neuralgia among older adults
48-50
.  
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